Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022.
Journal
European journal of anaesthesiology
ISSN: 1365-2346
Titre abrégé: Eur J Anaesthesiol
Pays: England
ID NLM: 8411711
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Management of peri-operative bleeding is complex and involves multiple assessment tools and strategies to ensure optimal patient care with the goal of reducing morbidity and mortality. These updated guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC) aim to provide an evidence-based set of recommendations for healthcare professionals to help ensure improved clinical management. A systematic literature search from 2015 to 2021 of several electronic databases was performed without language restrictions. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used to assess the methodological quality of the included studies and to formulate recommendations. A Delphi methodology was used to prepare a clinical practice guideline. These searches identified 137 999 articles. All articles were assessed, and the existing 2017 guidelines were revised to incorporate new evidence. Sixteen recommendations derived from the systematic literature search, and four clinical guidances retained from previous ESAIC guidelines were formulated. Using the Delphi process on 253 sentences of guidance, strong consensus (>90% agreement) was achieved in 97% and consensus (75 to 90% agreement) in 3%. Peri-operative bleeding management encompasses the patient's journey from the pre-operative state through the postoperative period. Along this journey, many features of the patient's pre-operative coagulation status, underlying comorbidities, general health and the procedures that they are undergoing need to be taken into account. Due to the many important aspects in peri-operative nontrauma bleeding management, guidance as to how best approach and treat each individual patient are key. Understanding which therapeutic approaches are most valuable at each timepoint can only enhance patient care, ensuring the best outcomes by reducing blood loss and, therefore, overall morbidity and mortality. All healthcare professionals involved in the management of patients at risk for surgical bleeding should be aware of the current therapeutic options and approaches that are available to them. These guidelines aim to provide specific guidance for bleeding management in a variety of clinical situations.
Sections du résumé
BACKGROUND
Management of peri-operative bleeding is complex and involves multiple assessment tools and strategies to ensure optimal patient care with the goal of reducing morbidity and mortality. These updated guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC) aim to provide an evidence-based set of recommendations for healthcare professionals to help ensure improved clinical management.
DESIGN
A systematic literature search from 2015 to 2021 of several electronic databases was performed without language restrictions. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used to assess the methodological quality of the included studies and to formulate recommendations. A Delphi methodology was used to prepare a clinical practice guideline.
RESULTS
These searches identified 137 999 articles. All articles were assessed, and the existing 2017 guidelines were revised to incorporate new evidence. Sixteen recommendations derived from the systematic literature search, and four clinical guidances retained from previous ESAIC guidelines were formulated. Using the Delphi process on 253 sentences of guidance, strong consensus (>90% agreement) was achieved in 97% and consensus (75 to 90% agreement) in 3%.
DISCUSSION
Peri-operative bleeding management encompasses the patient's journey from the pre-operative state through the postoperative period. Along this journey, many features of the patient's pre-operative coagulation status, underlying comorbidities, general health and the procedures that they are undergoing need to be taken into account. Due to the many important aspects in peri-operative nontrauma bleeding management, guidance as to how best approach and treat each individual patient are key. Understanding which therapeutic approaches are most valuable at each timepoint can only enhance patient care, ensuring the best outcomes by reducing blood loss and, therefore, overall morbidity and mortality.
CONCLUSION
All healthcare professionals involved in the management of patients at risk for surgical bleeding should be aware of the current therapeutic options and approaches that are available to them. These guidelines aim to provide specific guidance for bleeding management in a variety of clinical situations.
Identifiants
pubmed: 36855941
doi: 10.1097/EJA.0000000000001803
pii: 00003643-202304000-00002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-304Informations de copyright
Copyright © 2023 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.
Références
Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 2017; 34:332–395.
Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management. J Cardiothorac Vasc Anesth 2021; 35:2569–2591.
Mahawar KK, Himpens J, Shikora SA, et al. The First Consensus Statement on One Anastomosis/Mini Gastric Bypass (OAGB/MGB) using a modified Delphi approach. Obes Surg 2018; 28:303–312.
Mahawar KK, Himpens JM, Shikora SA, et al. The first consensus statement on revisional bariatric surgery using a modified Delphi approach. Surg Endosc 2020; 34:1648–1657.
Pouwels S, Omar I, Aggarwal S, et al. The first modified Delphi consensus statement for resuming bariatric and metabolic surgery in the COVID-19 times. Obes Surg 2021; 31:451–456.
De Robertis E, Longrois D. To streamline the guideline challenge: the European Society of Anaesthesiology policy on guidelines development. Eur J Anaesthesiol 2016; 33:794–799.
Munoz M, Gomez-Ramirez S, Campos A, et al. Preoperative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; 13:370–379.
Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in noncardiac surgery patients. Br J Anaesth 2014; 113:416–423.
Gombotz H, Rehak PH, Shander A, et al. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47:1468–1480.
Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in noncardiac surgery: a retrospective cohort study. Lancet 2011; 378:1396–1407.
Whitlock EL, Kim H, Auerbach AD. Harms associated with single unit perioperative transfusion: retrospective population based analysis. BMJ 2015; 350:h3037.
Allen CJ, Tashiro J, Valle EJ, et al. Initial hematocrit predicts the use of blood transfusion in the pediatric trauma patient. J Pediatr Surg 2014; 49:1678–1682.
Fontanals M, O’Leary JD, Zaarour C, et al. Preoperative anemia increases the risk of red blood cell transfusion and prolonged hospital length of stay in children undergoing spine arthrodesis surgery. Transfusion 2019; 59:492–499.
Faraoni D, DiNardo JA, Goobie SM. Relationship between preoperative anemia and in-hospital mortality in children undergoing noncardiac surgery. Anesth Analg 2016; 123:1582–1587.
Goobie SM, Faraoni D, Zurakowski D, et al. Association of preoperative anemia with postoperative mortality in neonates. JAMA Pediatr 2016; 170:855–862.
Browning RM, Trentino K, Nathan EA, et al. Western Australian Patient Blood Management Program. Preoperative anaemia is common in patients undergoing major gynaecological surgery and is associated with a fivefold increased risk of transfusion. Aust N Z J Obstet Gynaecol 2012; 52:455–459.
David O, Sinha R, Robinson K, et al. The prevalence of anaemia, hypochromia and microcytosis in preoperative cardiac surgical patients. Anaesth Intensive Care 2013; 41:316–321.
Gillard S, Van Aelbrouck C, El Kenz H, et al. Influence of haematocrit level on thromboelastometry parameters: 6AP5-10. Eur J Anaesthesiol 2014; 31:106.
Solomon C, Rahe-Meyer N, Schöchl H, et al. Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test. Blood Transfus 2013; 11:412–418.
Theusinger OM, Kind SL, Seifert B, et al. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus 2014; 12:195–203.
Meybohm P, Herrmann E, Steinbicker AU, et al. PBM-study Collaborators. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for ‘patient's outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg 2016; 264:203–211.
Althoff FC, Neb H, Herrmann E, et al. Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. Ann Surg 2019; 269:794–804.
Enko D, Wallner F, von-Goedecke A, et al. The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. Anemia 2013; 2013:641876.
Harwin SF, Pivec R, Naziri Q, et al. Is total hip arthroplasty a successful and safe procedure in Jehovah's Witnesses? Mean five-year results. Hip Int 2014; 24:69–76.
Qureshi M, Momoh I, Bankes M, et al. Erythropoietin provides a useful strategy for treating preoperative anemia in planned elective orthopedic surgery: an analysis of benefit in routine practice. Transfusion 2012; 52:2063–2064.
Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12:296–300.
Froessler B, Palm P, Weber I, et al. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg 2016; 264:41–46.
Rössler J, Schoenrath F, Seifert B, et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth 2020; 124:25–34.
Spahn DR, Schoenrath F, Spahn GH, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. Lancet 2019; 393:2201–2212.
Triphaus C, Judd L, Glaser P, et al. Effectiveness of preoperative iron supplementation in major surgical patients with iron deficiency: a prospective observational study. Ann Surg 2021; 274:e212–e219.
Bruce W, Campbell D, Daly D, et al. Practical recommendations for patient blood management and the reduction of perioperative transfusion in joint replacement surgery. ANZ J Surg 2013; 83:222–229.
Bisbe E, Munoz M. Management of preoperative anemia: the NATA consensus statements. ISBT Sci Ser 2012; 7:5.
Gurusamy KS, Nagendran M, Broadhurst JF, et al. Iron therapy in anaemic adults without chronic kidney disease. Cochrane Database Syst Rev 2014; 12:CD010640.
Lakkawar NJ, Rangaswamy T SS. Efficacy of intravenous administration of iron sucrose for treatment of iron deficiency anaemia in patients with abnormal uterine bleeding. Acta Fac Med Naissensis 2012; 29:10.
Keeler BD, Simpson JA, Ng S, et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis 2014; 16:794–800.
Quintana-Diaz M, Fabra-Cadenas S, Gomez-Ramirez S, et al. A fast-track anaemia clinic in the emergency department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia. Blood Transfus 2016; 14:126–133.
Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev 2013; 27:221–234.
Alsaleh K, Alotaibi GS, Almodaimegh HS, et al. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials. J Arthroplasty 2013; 28:1463–1472.
Cladellas M, Farré N, Comín-Colet J, et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol 2012; 110:1021–1026.
Doodeman HJ, van Haelst IM, Egberts TC, et al. The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice (CME). Transfusion 2013; 53:1930–1939.
Litton E, Baker S, Erber WN, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: a randomized trial of IV iron in critical illness. Intensive Care Med 2016; 42:1715–1722.
Tomeczkowski J, Stern S, Müller A, et al. Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model. PLoS One 2013; 8:e72949.
Wijnberge M, Rellum SR, de Bruin S, et al. Erythropoiesis-stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: a systematic review with meta-analysis. Transfus Med 2020; 30:433–441.
van Haelst IMM, Egberts ACG, Doodeman HJ, et al. Occurrence and determinants of poor response to short-term preoperative erythropoietin treatment. Acta Anaesthesiol Scand 2013; 57:350–357.
Litton E, Latham P, Inman J, et al. Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis. Intensive Care Med 2019; 45:1190–1199.
Kotzé A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. Br J Anaesth 2012; 108:943–952.
Menkis AH, Martin J, Cheng DC, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila) 2012; 7:229–241.
Leahy MF, Roberts H, Mukhtar SA, et al. Western Australian Patient Blood Management Program. A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion 2014; 54:1133–1145.
Collet JP, Thiele H, Barbato E, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42:1289–1367.
Devereaux PJ, Mrkobrada M, Sessler DI, et al. POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1494–1503.
Godier A, Fontana P, Motte S, et al. French Working Group on perioperative hemostasis (GIHP). Management of antiplatelet therapy in patients undergoing elective invasive procedures: proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Arch Cardiovasc Dis 2018; 111:210–223.
Filipescu DC, Stefan MG, Valeanu L, et al. Perioperative management of antiplatelet therapy in noncardiac surgery. Curr Opin Anesthesiol 2020; 33:454–462.
Au AG, Majumdar SR, McAlister FA. Preoperative thienopyridine use and outcomes after surgery: a systematic review. Am J Med 2012; 125:87.e1–99.e1.
Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012; 60:388–396.
Price MJ, Walder JS, Baker BA, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol 2012; 59:2338–2343.
Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015; 372:196–197.
Godier A, Albaladejo P. The French Working Group On Perioperative Haemostasis Gihp Group. Management of bleeding events associated with antiplatelet therapy: evidence, uncertainties and pitfalls. J Clin Med 2020; 9:2318.
Godier A, Garrigue D, Lasne D, et al. Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med 2019; 38:289–302.
O’Connor SA, Amour J, Mercadier A, et al. ACTION Study Group. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv 2015; 8:e002786.
Pehrsson S, Johansson KJ, Janefeldt A, et al. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. J Thromb Haemost 2017; 15:1213–1222.
Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019; 380:1825–1833.
Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: the Joint Task Force on noncardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014; 31:517–573.
Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119–177.
Hawn MT, Graham LA, Richman JS, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 2013; 310:1462–1472.
Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ’bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104:285–291.
Warshauer J, Patel VG, Christopoulos G, et al. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Catheter Cardiovasc Interv 2015; 85:25–31.
Steg PG, Bhatt DL, Hamm CW, et al. CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382:1981–1992.
Angiolillo D, Firstenberg M, Price M, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307:265–274.
Fazavana J, Bianchini EP, Saller F, et al. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J Thromb Haemost 2013; 11:1128–1136.
Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfus Med 2012; 22:108–115.
Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med 2015; 175:1163–1168.
Douketis JD, Spyropoulos AC, Kaatz S, et al. BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373:823–833.
Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost 2015; 13:182–190.
Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S–350S.
Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC Expert Consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69:871–898.
Baumgartner C, de Kouchkovsky I, Whitaker E, et al. Periprocedural bridging in patients with venous thromboembolism: a systematic review. Am J Med 2019; 132:722.e7–732.e7.
Nikolakopoulos I, Spyropoulos AC. Heparin bridging therapy for patients on chronic oral anticoagulants in periprocedural settings. Semin Thromb Hemost 2020; 46:26–31.
van der Pol S, Jacobs MS, Meijer K, et al. Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits. Europace 2019; 21:716–723.
Kovacs MJ, Wells PS, Anderson DR, et al. PERIOP2 Investigators. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ 2021; 373:n1205.
Colomina MJ, Diez Lobo A, Garutti I, et al. Perioperative use of prothrombin complex concentrates. Minerva Anestesiol 2012; 78:358–368.
Makris M, Van Veen JJ, Tait CR, et al. British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160:35–46.
Pernod G, Godier A, Gozalo C, et al. French National Authority for Haematology. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126:e167–e174.
Tran HA, Chunilal SD, Harper PL, et al. Australasian Society of Thrombosis and Haemostasis (ASTH). An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198:198–199.
Hunt BJ, Levi M. Urgent reversal of vitamin K antagonists. BMJ 2018; 360:j5424.
Godier A, Dincq AS, Martin AC, et al. Predictors of preprocedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38:2431–2439.
Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179:1469–1478.
Ferrandis R, Llau JV, Sanz JF, et al. RA-ACOD investigators. Periprocedural direct oral anticoagulant management: the RA-ACOD prospective, multicenter real-world registry. TH Open 2020; 4:e127–e137.
Sie P, Samama CM, Godier A, et al. Working Group on Perioperative Haemostasis, French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104:669–676.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2015; 17:1467–1507.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of nonvitamin-K antagonist anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J 2017; 38:2137–2149.
Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14:147–154.
Lehmann T, Hofer KE, Baumann M, et al. Massive human rivaroxaban overdose. Thromb Haemost 2014; 112:834–836.
Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109:596–605.
Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014; 111:189–198.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573–1579.
Majeed A, Agren A, Holmstrom M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130:1706–1712.
Piran S, Khatib R, Schulman S, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv 2019; 3:158–167.
Piran S, Gabriel C, Schulman S. Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. J Thromb Thrombolysis 2018; 45:486–495.
Barzilai M, Kirgner I, Steimatzky A, et al. Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban. Acta Haematol 2020; 143:266–271.
Dager WE, Roberts AJ, Nishijima DK. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thromb Res 2019; 173:71–76.
Albaladejo P, Samama CM, Sie P, et al. GIHP-NACO Study Group. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology 2017; 127:111–120.
Levy JH, van Ryn J, Sellke FW, et al. Dabigatran reversal with idarucizumab in patients requiring urgent surgery: a subanalysis of the RE-VERSE AD Study. Ann Surg 2021; 274:e204–e211.
Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386:680–690.
Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373:511–520.
Hegemann I, Ganter C, Widmer CC, et al. Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab. Br J Anaesth 2018; 121:505–508.
Connolly SJ, Crowther M, Eikelboom JW, et al. ANNEXA-4 Investigators. Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326–1335.
Nederpelt CJ, Naar L, Sylvester KW, et al. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. J Thromb Haemost 2020; 18:2532–2541.
Nederpelt CJ, Naar L, Krijnen P, et al. Andexanet Alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis. Crit Care Med 2021; 49:e1025–e1036.
Gomez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol 2021; 77:2987–3001.
Pluta J, Nicińska B, Grzeszczyk M, et al. Assessment of the hemostatic parameters and platelet function on thromboelastometry and impedance aggregometry in hemodialysis patients qualified for kidney transplantation: preliminary report. Transplant Proc 2016; 48:1431–1434.
Ranghino A, Mella A, Borchiellini A, et al. Assessment of platelet function analyzer (PFA-100) in kidney transplant patients before renal allograft biopsy: a retrospective single-center analysis. Transplant Proc 2014; 46:2259–2262.
Peters B, Hadimeri H, Mölne J, et al. Desmopressin (Octostim®) before a native kidney biopsy can reduce the risk for biopsy complications in patients with impaired renal function: a pilot study. Nephrology (Carlton) 2018; 23:366–370.
Kim JH, Baek CH, Min JY, et al. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol 2015; 94:1457–1461.
Athavale A, Kulkarni H, Arslan CD, et al. Desmopressin and bleeding risk after percutaneous kidney biopsy. BMC Nephrol 2019; 20:413.
Lambert MP. Platelets in liver and renal disease. Hematology Am Soc Hematol Educ Program 2016; 2016:251–255.
Lim CC, Siow B, Choo JCJ, et al. Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia. Int Urol Nephrol 2019; 51:995–1004.
Gonzalez J, Bryant S, Hermes-DeSantis ER. Transdermal estradiol for the management of refractory uremic bleeding. Am J Health Syst Pharm 2018; 75:e177–e183.
Pei J, Harakalova M, den Ruijter H, et al. Cardiorenal disease connection during postmenopause: the protective role of estrogen in uremic toxins induced microvascular dysfunction. Int J Cardiol 2017; 238:22–30.
Franchini M, Lippi G, Manzato F, et al. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol 2010; 162:439–451.
Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemost 2018; 16:634–645.
Lupoli R, Di Minno MN, Tortora A, et al. Primary and secondary hemostasis in patients with subclinical hypothyroidism: effect of levothyroxine treatment. J Clin Endocrinol Metab 2015; 100:2659–2665.
Thoyyib M, Garg S, Gupta N, et al. Study on coagulation factor VIII and fibrinogen levels in patients with thyroid disorders. Indian J Endocrinol Metab 2018; 22:479–484.
Kyriakakis N, Lynch J, Ajjan R, et al. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications. Clin Endocrinol (Oxf) 2016; 84:473–484.
Ordookhani A, Burman KD. Hemostasis in hypothyroidism and autoimmune thyroid disorders. Int J Endocrinol Metab 2017; 15:e42649.
Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. Int J Endocrinol Metab 2017; 15:e44157.
Horacek J, Maly J, Svilias I, et al. Prothrombotic changes due to an increase in thyroid hormone levels. Eur J Endocrinol 2015; 172:537–542.
Ellervik C, Mora S, Kus A, et al. Effects of thyroid function on hemostasis, coagulation, and fibrinolysis: a Mendelian randomization study. Thyroid 2021; 31:1305–1315.
Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015; 173:R101–R113.
Coelho MC, Santos CV, Vieira Neto L, et al. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol 2015; 173:M11–M21.
Kastelan D, Dusek T, Kraljevic I, et al. Hypercoagulable state in Cushing's syndrome is reversible following remission. Clin Endocrinol (Oxf) 2013; 78:102–106.
Fischli S, von Wyl V, Wuillemin W, et al. Impact of adrenal function on hemostasis/endothelial function in patients undergoing surgery. J Endocr Soc 2021; 5:bvab047.
Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. Front Pharmacol 2021; 11:554961.
Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol 2018; 40:215–224.
Khunger J, Malhotra M, Kumar N, et al. To study the coagulation profile derangements in metabolic syndrome. Blood 2019; 134:4959–14959.
Pedro-Botet J, Ascaso JF, Barrios V, et al. COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes Metab Syndr Obes 2018; 11:683–697.
Franchini M, Castaman G, Coppola A, et al. AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus 2015; 13:498–513.
Ko HC, Rojas Hernandez C, Oo TH. Clinical outcomes of acquired factor VIII inhibitors in cancer population: a systematic review. Blood 2017; 130:5639–15639.
Napolitano M, Siragusa S, Mancuso S, et al. Acquired haemophilia in cancer: a systematic and critical literature review. Haemophilia 2018; 24:43–56.
Dejhansathit S, Suvannasankha A. Acquired factor X deficiency in patients with primary light chain amyloidosis. J Investig Med High Impact Case Rep 2019; 7:2324709619832332.
Abdallah N, Muchtar E, Dispenzieri A, et al. Coagulation abnormalities in light chain amyloidosis. Mayo Clin Proc 2021; 96:377–387.
Arahata M, Takamatsu H, Morishita E, et al. Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. Int J Hematol 2020; 111:550–558.
Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010; 85:171–173.
Debernardi Venon W, Ponzo P, Sacco M, et al. Usefulness of thromboelastometry in predicting the risk of bleeding in cirrhotics who undergo invasive procedures. Eur J Gastroenterol Hepatol 2015; 27:1313–1319.
Seeßle J, Löhr J, Kirchner M, et al. Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and non-ACLF patients. BMC Gastroenterol 2020; 20:271.
O’Leary JG, Greenberg CS, Patton HM, et al. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology 2019; 157:34.e1–43.e1.
Somani V, Amarapurkar D, Shah A. Thromboelastography for assessing the risk of bleeding in patients with cirrhosis-moving closer. J Clin Exp Hepatol 2017; 7:284–289.
Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med 2017; 38:79–82.
Lin S, Wang M, Zhu Y, et al. Hemorrhagic complications following abdominal paracentesis in acute on chronic liver failure a propensity score analysis. Medicine (United States) 2015; 94:e2225.
Wooley R, Kim S, Guevarra K. Thoracentesis in cirrhotics (TIC study): incidence of hemorrhagic complications of thoracentesis in cirrhotic patients. Chest 2016; 150: (4 Suppl 1): 1000A.
Podda GM, Ronca V, Santambrogio R, et al. The association between platelet count and perioperative bleeding complication in a cohort of cirrhotic patients undergoing surgical excision of hepatocellular carcinoma. Blood Transfus 2020; 18: (Suppl 4): S427.
Ronca V, Podda G, Santambrogio R, et al. The association between platelet count and perioperative bleeding complication in a cohort of cirrhotic patients undergoing surgical excision of hepatocellular carcinoma. Res Pract Thromb Haemost 2020; 4: (Suppl 1): 41.
Basili S, Raparelli V, Napoleone L, et al. PRO-LIVER Collaborators. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER Study. Am J Gastroenterol 2018; 113:368–375.
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73:366–413.
Simonetto DA, Singal AK, Garcia-Tsao G, et al. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol 2020; 115:18–40.
Pandey CK, Saluja V, Gaurav K, et al. K time & maximum amplitude of thromboelastogram predict postcentral venous cannulation bleeding in patients with cirrhosis: a pilot study. Indian J Med Res 2017; 145:84–89.
Zanetto A, Rinder HM, Senzolo M, et al. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. Hepatol Commun 2021; 5:272–282.
Rout G, Shalimar, Gunjan D, et al. Thromboelastography-guided blood product transfusion in cirrhosis patients with variceal bleeding: a randomized controlled trial. J Clin Gastroenterol 2020; 54:255–262.
Kumar M, Ahmad J, Maiwall R, et al. Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal bleeding: a randomized controlled trial. Hepatology 2020; 71:235–246.
Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol 2019; 17:1192–1200.
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology 2019; 70:1336–1348.
Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 2018; 155:705–718.
Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: a meta-analysis. Dig Liver Dis 2019; 51:24–27.
Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117:139–148.
Raparelli V, Basili S, Carnevale R, et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology 2017; 65:571–581.
Lisman T, Violi F. Cirrhosis as a risk factor for venous thrombosis. Thromb Haemost 2017; 117:3–5.
Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 2021; 19:1116–1122.
Hugenholtz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14:1054–1066.
Verbeek TA, Stine JG, Saner FH, et al. Hypercoagulability in end-stage liver disease: review of epidemiology, etiology, and management. Transplant Direct 2018; 4:e403.
Ciavarella A, Gnocchi D, Custodero C, et al. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021; 198:139–150.
Driever EG, Stravitz RT, Zhang J, et al. VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in acute liver failure. Hepatology 2021; 73:1882–1891.
Stravitz RT, Ellerbe C, Durkalski V, et al. Thrombocytopenia is associated with multiorgan system failure in patients with acute liver failure. Clin Gastroenterol Hepatol 2016; 14:613.e4–620.e4.
Stravitz RT, Fontana RJ, Meinzer C, et al. Coagulopathy, bleeding events and outcome according to rotational thromboelastometry in patients with acute liver injury/failure. Hepatology 2021; 26:937–949.
Warrillow S, Fisher C, Tibballs H, et al. Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand. J Gastroenterol Hepatol 2020; 35:846–854.
Wendon J, Cordoba J, Dhawan A, et al. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66:1047–1081.
Jinadasa SP, Ruan QZ, Bayoumi AB, et al. Hemorrhagic complications of invasive intracranial pressure monitor placement in acute liver failure: outcomes of a single-center protocol and comprehensive literature review. Neurocrit Care 2020; 35:87–102.
Rajajee V, Fontana RJ, Courey AJ, et al. Protocol based invasive intracranial pressure monitoring in acute liver failure: feasibility, safety and impact on management. Crit Care 2017; 21:178.
Maloney PR, Mallory GW, Atkinson JL, et al. Intracranial pressure monitoring in acute liver failure: institutional case series. Neurocrit Care 2016; 25:86–93.
McCloskey DJ, Postolache TT, Vittone BJ, et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151:168–172.
Shepherd SJ, Fiandeiro C, Sanders RD. Selective serotonin reuptake inhibitors: depressing perioperative outcomes? Br J Anaesth 2015; 115:5–7.
Yuet WC, Derasari D, Sivoravong J, et al. Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding. J Osteopath Med 2019; 119:102–111.
Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother 2018; 53:186–194.
Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13:42.e3–50.e3.
Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016; 85:270–288.
Cheng YL, Hu HY, Lin XH, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore) 2015; 94:e2022.
Renoux C, Vahey S, Dell’Aniello S, et al. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 2017; 74:173–180.
Morriss R. Antidepressants are associated with hospital admitted intracranial bleeds in people taking other medication associated with bleeding. Evid Based Ment Health 2016; 19:24.
Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of nonsteroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351:h3517.
Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol 2014; 114:583–586.
Quinn GR, Hellkamp AS, Hankey GJ, et al. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF Trial. J Am Heart Assoc 2018; 7:e008755.
Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835–1843.
Ellero-Simatos S, Lewis J, Georgiades A, et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol 2014; 3:125.
Roose SP, Rutherford BR. Selective serotonin reuptake inhibitors and operative bleeding risk: a review of the literature. J Clin Psychopharmacol 2016; 36:704–709.
Gahr M, Zeiss R, Lang D, et al. Risk of bleeding related to selective and nonselective serotonergic antidepressants: a case/noncase approach using data from two pharmacovigilance databases. Pharmacopsychiatry 2015; 48:19–24.
Gagne JJ, Polinski JM, Rassen JA, et al. Selective serotonin reuptake inhibitor use and perioperative bleeding and mortality in patients undergoing coronary artery bypass grafting: a cohort study. Drug Saf 2015; 38:1075–1082.
Eckersley MJ, Sepehripour AH, Casula R, et al. Do selective serotonin reuptake inhibitors increase the risk of bleeding or mortality following coronary artery bypass graft surgery? A meta-analysis of observational studies. Perfusion 2018; 33:415–422.
Belay ES, Penrose CT, Ryan SP, et al. Perioperative selective serotonin reuptake inhibitor use is associated with an increased risk of transfusion in total hip and knee arthroplasty. J Arthroplasty 2019; 34:2898–2902.
Jiang HY, Xu LL, Li YC, et al. Antidepressant use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Psychiatr Res 2016; 83:160–167.
Singh I, Achuthan S, Chakrabarti A, et al. Influence of preoperative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf 2015; 24:237–245.
Jeong BO, Kim SW, Kim SY, et al. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics 2014; 55:213–220.
Zhou C, Sui Y, Zhao W, et al. The critical interaction between valproate sodium and warfarin: case report and review. BMC Pharmacol Toxicol 2018; 19:60.
Clark NP, Hoang K, Delate T, et al. Warfarin interaction with hepatic cytochrome P-450 enzyme-inducing anticonvulsants. Clin Appl Thromb Hemost 2017; 24:172–178.
Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol 2018; 9:1067.
Fajardo A, Olmos F, Sarmiento L. Valproic acid and the risk of perioperative bleeding. Case report and literature review. Colomb J Anesthesiol 2013; 41:61–64.
Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006; 47:1136–1143.
Manohar C, Avitsian R, Lozano S, et al. The effect of antiepileptic drugs on coagulation and bleeding in the perioperative period of epilepsy surgery: the Cleveland Clinic experience. J Clin Neurosci 2011; 18:1180–1184.
Kumar R, Vidaurre J, Gedela S. Valproic acid-induced coagulopathy. Pediatr Neurol 2019; 98:25–30.
Buoli M, Serati M, Botturi A, et al. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. Drugs R D 2018; 18:1–5.
Zighetti ML, Fontana G, Lussana F, et al. Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis. Epilepsia 2015; 56:e49–e52.
Kurwale N, Garg K, Arora A, et al. Valproic acid as an antiepileptic drug: is there a clinical relevance for the epilepsy surgeon? Epilepsy Res 2016; 127:191–194.
Carney BT, Minter CL. Is operative blood loss associated with valproic acid?: analysis of bilateral femoral osteotomy in children with total involvement cerebral palsy. J Pediatr Orthop 2005; 25:283–285.
McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost 2015; 41:300–314.
Tsai C-H, Chung H-J, Huang EYH, et al. Prolonged warm ischemic time is a significant risk factor of hemorrhagic complication in patients who received robotic assisted partial nephrectomy. J Urol 2020; 203:E318.
Zhuang W, Liu S, Zhao X, et al. Interaction between Chinese medicine and warfarin: clinical and research update. Front Pharmacol 2021; 12:751107.
Shiyong Y, Yijia X, Peng Z, et al. Ginkgo biloba extract inhibits platelet activation via inhibition of Akt. Integr Med Int 2014; 1:234–242.
Yagmur E, Piatkowski A, Gröger A, et al. Bleeding complication under Gingko biloba medication. Am J Hematol 2005; 79:343–344.
Köhler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004; 15:303–309.
Bent S, Goldberg H, Padula A, et al. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med 2005; 20:657–661.
Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011; 31:490–502.
Kim HS, Kim GY, Yeo CW, et al. The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. Br J Clin Pharmacol 2014; 77:821–830.
Hu Y, Wang J. Interactions between clopidogrel and traditional Chinese medicine. J Thromb Thrombolysis 2019; 48:491–499.
Kim BH, Kim KP, Lim KS, et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010; 32:380–390.
Ke J, Li MT, Huo YJ, et al. The synergistic effect of Ginkgo biloba extract 50 and aspirin against platelet aggregation. Drug Des Devel Ther 2021; 15:3543–3560.
Li J, Liang Q, Sun G. Interaction between traditional Chinese medicine and anticoagulant/antiplatelet drugs. Curr Drug Metab 2019; 20:701–713.
McEwen BJ. The influence of diet and nutrients on platelet function. Semin Thromb Hemost 2014; 40:214–226.
McEwen BJ, Morel-Kopp MC, Chen W, et al. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost 2013; 39:25–32.
McEwen BJ, Morel-Kopp MC, Tofler GH, et al. The effect of omega-3 polyunsaturated fatty acids on fibrin and thrombin generation in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost 2015; 41:315–322.
Golanski J, Szymanska P, Rozalski M. Effects of omega-3 polyunsaturated fatty acids and their metabolites on haemostasis-current perspectives in cardiovascular disease. Int J Mol Sci 2021; 22:2394.
Rodeghiero F, Pabinger I, Ragni M, et al. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA Consensus Report. HemaSphere 2019; 3:e286.
Ambaglio C, Zane F, Russo MC, et al. Preoperative bleeding risk assessment with ISTH-BAT and laboratory tests in patients undergoing elective surgery: a prospective cohort study. Haemophilia 2021; 27:717–723.
Vries MJ, van der Meijden PE, Kuiper GJ, et al. Preoperative screening for bleeding disorders: a comprehensive laboratory assessment of clinical practice. Res Pract Thromb Haemost 2018; 2:767–777.
Moenen FCJI, Nelemans PJ, Schols SEM, et al. The diagnostic accuracy of bleeding assessment tools for the identification of patients with mild bleeding disorders: a systematic review. Haemophilia 2018; 24:525–535.
Fasulo MR, Biguzzi E, Abbattista M, et al. The ISTH Bleeding Assessment Tool and the risk of future bleeding. J Thromb Haemost 2017; 16:125–130.
Gebhart J, Hofer S, Kaider A, et al. The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. Eur J Intern Med 2020; 78:34–40.
Adler M, Kaufmann J, Alberio L, et al. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. J Thromb Haemost 2019; 17:1104–1112.
Gresele P, Orsini S, Noris P, et al. BAT-VAL study investigators. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC. J Thromb Haemost 2019; 18:732–739.
Gresele P, Falcinelli E, Bury L, et al. BAT-VAL Study Investigators. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2021; 19:1364–1371.
Borhany M, Fatima N, Abid M, et al. Application of the ISTH bleeding score in hemophilia. Transfus Apher Sci 2018; 57:556–560.
Toret E, Ay Y, Karapinar TH, et al. Evaluation of bleeding phenotype of inherited factor VII deficiency in children with a bleeding assessment tool and global assays. J Pediatr Hematol Oncol 2019; 42:e527–e530.
Saes JL, Verhagen MJA, Meijer K, et al. Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood Adv 2020; 4:5025–5034.
Palla R, Siboni SM, Menegatti M, et al. European Network of Rare Bleeding Disorders (EN-RBD) group. Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thromb Res 2016; 148:128–134.
Smilowitz NR, Gupta N, Guo Y, et al. Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease. J Thromb Thrombolysis 2017; 44:67–70.
Orsini S, Noris P, Bury L, et al. European Hematology Association – Scientific Working Group (EHA-SWG) on thrombocytopenias and platelet function disorders. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica 2017; 102:1192–1203.
Clarke L, Dennington PM, Curnow J. Elective surgery in patients with inherited bleeding disorders: a retrospective analysis. Haemophilia 2021; 27:744–750.
Chapin J, Bamme J, Hsu F, et al. Outcomes in patients with hemophilia and von Willebrand disease undergoing invasive or surgical procedures. Clin Appl Thromb Hemost 2016; 23:148–154.
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26: (Suppl 6): 1–158.
Coppola A, Windyga J, Tufano A, et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev 2015; 2:CD009961.
Gill JC, Conley SF, Johnson VP, et al. Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy. Blood Adv 2020; 4:100–105.
Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019; 133:415–424.
Maas D, Saes JL, Blijlevens NMA, et al. RBiN study group. Treatment of patients with rare bleeding disorders in the Netherlands: real-life data from the RBiN study. J Thromb Haemost 2022; 20:833–844.
Azer SM, Eckerman AL, Rodriguez V, et al. Hemostatic prophylaxis and colonoscopy outcomes for patients with bleeding disorders: a retrospective cohort study and review of the literature. Haemophilia 2020; 26:257–268.
Bajkin B, Dougall A. Current state of play regarding dental extractions in patients with haemophilia: consensus or evidence-based practice? A review of the literature. Haemophilia 2020; 26:183–199.
Ariëns RA, Kohler HP, Mansfield MW, et al. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19:2012–2016.
Biswas A, Ivaskevicius V, Thomas A, et al. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014; 34:160–166.
Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5:301–325.
Brignardello-Petersen R, El Alayli A, Husainat N, et al. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Adv 2022; 6:121–128.
Hermans C, Apte S, Santagostino E. Invasive procedures in patients with haemophilia: review of low-dose protocols and experience with extended half-life FVIII and FIX concentrates and nonreplacement therapies. Haemophilia 2020; 27:46–52.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2012; 19:e1–e47.
van Moort I, Preijers T, Bukkems LH, et al. OPTI-CLOT study group. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematol 2021; 8:e492–e502.
Hazendonk HCAM, Preijers T, Liesner R, et al. Perioperative replacement therapy in haemophilia B: an appeal to “B” more precise. Haemophilia 2018; 24:611–618.
Keipert C, Drechsel-Bäuerle U, Oberle D, et al. Epidemiological challenges in rare bleeding disorders: FVIII inhibitor incidence in haemophilia a patients-a known issue of unknown origin. Int J Environ Res Public Health 2020; 18:225.
Sande CM, Al-Huniti A, Ten Eyck P, et al. Impact of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: a survey of Haemophilia and Thrombosis Research Society members. Haemophilia 2019; 25:764–772.
Peyvandi F, Miri S, Garagiola I. Immune responses to plasma-derived versus recombinant FVIII products. Front Immunol 2021; 11:591878–591878.
Peyvandi F, Cannavò A, Garagiola I, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost 2017; 16:39–43.
Messori A, Peyvandi F, Mengato D, et al. Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies. Haemophilia 2017; 23:e87–e92.
Rota M, Cortesi PA, Steinitz-Trost KN, et al. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. Blood Coagul Fibrinolysis 2017; 28:627–637.
Gruppo R, López-Fernández M-F, Wynn TT, et al. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial. Haemophilia 2019; 25:773–781.
Santagostino E, Lalezari S, Reding MT, et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial. Thromb Res 2019; 183:13–19.
Tosetto A, Neff A, Lentz SR, et al. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: full data set from the pathfinder 3 and 5 phase III trials. Haemophilia 2020; 26:450–458.
Escobar MA, Tehranchi R, Karim FA, et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia 2016; 23:67–76.
Chai-Adisaksopha C, Nevitt SJ, Simpson ML, et al. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev 2017; 9:CD011441.
Poon M-C, d’Oiron R, Zotz RB, et al. Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 2015; 100:1038–1044.
Di Minno G, Zotz RB, d’Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of nonsurgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 2015; 100:1031–1037.
Al-Riyami AZ, Jug R, La Rocca U, et al. Quality of evidence-based guidelines for platelet transfusion and use: a systematic review. Transfusion 2021; 61:948–958.
Windyga J, Dolan G, Altisent C, et al. EHTSB. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey. Haemophilia 2015; 22:110–120.
Atiq F, Schütte LM, Looijen AEM, et al. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Adv 2019; 3:4147–4154.
Stoof SCM, Schütte LM, Leebeek FWG, et al. Desmopressin in haemophilia: the need for a standardised clinical response and individualised test regimen. Haemophilia 2017; 23:861–867.
Schütte L, van Hest R, Stoof S, et al. Pharmacokinetic modelling to predict FVIII:C response to desmopressin and its reproducibility in nonsevere haemophilia a patients. Thromb Haemost 2018; 47:621–629.
Loomans JI, Kruip MJHA, Carcao M, et al. RISE consortium. Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica 2018; 103:550–557.
Kleiboer B, Layer MA, Cafuir LA, et al. Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: a prospective multicenter observational study. J Thromb Haemost 2022; 20:857–865.
Huang ZY, Huang Q, Zeng HJ, et al. Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia. BMC Musculoskelet Disord 2019; 20:402.
van Galen KP, Engelen ET, Mauser-Bunschoten EP, et al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2019; 4:CD011385.
Lewandowski B, Wojnar J, Brodowski R, et al. Dental extractions in patients of mild level hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation. Pol Arch Intern Med 2018; 128:488–490.
Poon MC. The use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia. Thromb Haemost 2021; 121:332–340.
Recht M, Rajpurkar M, Chitlur M, et al. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. Am J Hematol 2017; 92:646–652.
Zotz RB, Poon M-C, Di Minno G, et al. Glanzmann Thrombasthenia Registry Investigators. The International Prospective Glanzmann Thrombasthenia Registry: pediatric treatment and outcomes. TH Open 2019; 3:e286–e294.
Di Minno MND, Napolitano M, Dolce A, et al. STER Study Group. Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry. Brit J Haematol 2017; 180:563–570.
Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120:998–1000.
Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844–847.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062.
Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18:1738–1742.
Panigada M, Zacchetti L, L’Acqua C, et al. Assessment of fibrinolysis in sepsis patients with urokinase modified thromboelastography. PLoS One 2015; 10:e0136463.
Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 2020; 231:193.e1–203.e1.
Nougier C, Benoit R, Simon M, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020; 18:2215–2219.
Bachler M, Bösch J, Stürzel DP, et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth 2021; 126:590–598.
Martinelli I, Ciavarella A, Abbattista M, et al. Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med 2021; 16:1223–1229.
Pavoni V, Gianesello L, Pazzi M, et al. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to action. Thromb Res 2020; 196:313–317.
Beun R, Kusadasi N, Sikma M, et al. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42: (Suppl 1): 19–20.
White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020; 50:287–291.
Lopes RD, de Barros ESPGM, Furtado RHM, et al. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J 2021; 238:1–11.
Sadeghipour P, Talasaz AH, et al. INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial. JAMA 2021; 325:1620–1630.
The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Zarychanski R. Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report. medRxiv 2021. 10.1101/2021.03.10.21252749.
Stillson JE, Bunch CM, Gillespie L, et al. Thromboelastography-guided management of anticoagulated COVID-19 patients to prevent hemorrhage. Semin Thromb Hemost 2021; 47:442–446.
Trunfio M, Salvador E, Cabodi D, et al. e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thromb Res 2020; 196:432–434.
Toor R, Zamora FJ, Fatteh N, et al. Use of low-molecular-weight heparin and peak anti-Xa monitoring in severe SARS-CoV-2 disease: a brief report. Hosp Pharm 2021; 56:640–645.
Zufferey PJ, Dupont A, Lanoiselée J, et al. Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. Thromb Res 2021; 205:120–127.
Kofteridis DP, Ioannou P, Kondili E, et al. Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 - the role of anti-Xa monitoring. Clin Microbiol Infect 2021; 27:1188–1189.
Novelli C, Borotto E, Beverina I, et al. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. Int J Lab Hematol 2021; 43:1284–1290.
Stessel B, Vanvuchelen C, Bruckers L, et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study. Thromb Res 2020; 194:209–215.
Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth 2015; 115:376–385.
Xiao F, Wu H, Sun H, et al. Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: a propensity score-matched study of 1418 patients. PLoS One 2015; 10:e0116311.
Hwang D, Lee JM, Rhee T-M, et al. The effects of preoperative aspirin on coronary artery bypass surgery: a systematic meta-analysis. Korean Circ J 2019; 49:498–510.
Sharifi M, Kamali A, Ghandi Y. Effect of sustained use of aspirin until the time of surgery on outcomes following coronary artery bypass grafting: a randomized clinical trial. Thorac Cardiovasc Surg 2018; 66:442–451.
Myles PS, Smith JA, Forbes A, et al. ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376:136–148.
Vorobcsuk A, Aradi D, Farkasfalvi K, et al. Outcomes of patients receiving clopidogrel prior to cardiac surgery. Int J Cardiol 2012; 156:34–40.
Blais DM, Zukkoor SM, Hayes C, et al. Bleeding outcomes associated with coronary artery bypass graft surgery and recent clopidogrel exposure. Heart Surg Forum 2012; 16:E70–E77.
Guay J, Andrew Ochroch E. Continuing antiplatelet therapy before cardiac surgery with cardiopulmonary bypass: a meta-analysis on the need for reexploration and major outcomes. J Cardiothorac Vasc Anesth 2014; 28:90–97.
Rossini R, Musumeci G, Capodanno D, et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost 2015; 113:272–282.
Pickard AS, Becker RC, Schumock GT, et al. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy 2008; 28:376–392.
Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006; 92:531–532.
Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994–2002.
Malm CJ, Hansson EC, Akesson J, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth 2016; 117:309–315.
Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5:261–269.
Bobbitt J, Petro K, Martin M. Evaluating the effectiveness of preoperative platelet inhibition testing to reduce costs and preoperative length of stay. Appl Nurs Res 2018; 39:241–243.
Vonk AB, Veerhoek D, van den Brom CE, et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28:235–241.
Guo Y, Tang J, Du L, et al. Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: a prospective, double-blinded, randomized study. Can J Cardiol 2012; 28:547–552.
Meesters MI, Veerhoek D, de Lange F, et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery: a randomised clinical trial. Thromb Haemost 2016; 116:251–261.
Guo J, Gao X, Ma Y, et al. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. BMC Anesthesiol 2019; 19:129.
Takagi H, Ando T, Umemoto T. Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and nonrandomized studies. J Card Surg 2017; 58:633–641.
Waldow T, Szlapka M, Haferkorn M, et al. Prospective clinical trial on dosage optimizing of tranexamic acid in nonemergency cardiac surgery procedures. Clin Hemorheol Microcirc 2013; 55:457–468.
Zufferey PJ, Lanoiselee J, Graouch B, et al. Exposure-response relationship of tranexamic acid in cardiac surgery. Anesthesiology 2021; 134:165–178.
Vaněk T, Straka Z. Topical use of tranexamic acid in cardiac surgery—a review and meta-analysis of four randomized controlled trials. Cor et Vasa 2013; 55:e184–e189.
Chaudhary FA, Pervaz Z, Ilyas S, et al. Topical use of tranexamic acid in open heart surgery. J Pak Med Assoc 2018; 68:538–542.
Shah MUA, Asghar MI, Siddiqi R, et al. Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact? J Coll Physicians Surg Pak 2015; 25:161–165.
Habbab LM, Hussain S, Power P, et al. Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) study: results of a pilot study. J Card Surg 2019; 34:305–311.
Habbab LM, Semelhago L, Lamy A. Topical use of tranexamic acid in cardiac surgery: a meta-analysis. Thorac Cardiovasc Surg 2020; 68:212–218.
Faraoni D, Willems A, Melot C, et al. Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2012; 42:781–786.
Siemens K, Sangaran DP, Hunt BJ, et al. Antifibrinolytic drugs for the prevention of bleeding in pediatric cardiac surgery on cardiopulmonary bypass: a systematic review and meta-analysis. Anesth Analg 2022; 134:987–1001.
Hatami F, Valizadeh N, Salehi F, et al. Topical versus low-dose systemic tranexamic acid in pediatric cardiac surgery: a randomized clinical study. J Card Surg 2020; 35:3368–3373.
Gurian DB, Meneghini A, de Abreu LC, et al. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost 2014; 20:616–620.
Choudhuri P, Biswas BK. Intraoperative use of epsilon amino caproic acid and tranexamic acid in surgeries performed under cardiopulmonary bypass: a comparative study to assess their impact on reopening due to postoperative bleeding. Ethiop J Health Sci 2015; 25:273–278.
Gatling J, Ramsingh D, Horricks J, et al. Blood conservation using tranexamic acid versus epsilon aminocaproic acid in cardiac surgery: a randomized controlled trial. J Anesth Perioper Med 2018; 5:169–175.
Leff J, Rhee A, Nair S, et al. A randomized, double-blinded trial comparing the effectiveness of tranexamic acid and epsilon-aminocaproic acid in reducing bleeding and transfusion in cardiac surgery. Ann Card Anaesth 2019; 22:265–272.
Makhija N, Sarupria A, Kumar Choudhary S, et al. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013; 27:1201–1207.
Lu J, Meng H, Meng Z, et al. Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials. Int J Clin Exp Pathol 2015; 8:7978–7987.
Martin K, Gertler R, MacGuill M, et al. Replacement of aprotinin by epsilon-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome. Br J Anaesth 2013; 110:615–621.
Klein A, Agarwal S, Cholley B, et al. A survey of patient blood management for patients undergoing cardiac surgery in nine European countries. J Clin Anesth 2021; 72:110311.
Hutton B, Joseph L, Fergusson D, et al. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 2012; 345:e5798.
Karkouti K, Wijeysundera DN, Yau TM, et al. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110:21–29.
Meybohm P, Herrmann E, Nierhoff J, et al. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and (epsilon)-aminocaproic acid - a meta-analysis of randomised and observational trials of over 30.000 patients. PLoS One 2013; 8:e58009.
Benedetto U, Altman DG, Gerry S, et al. Safety of perioperative aprotinin administration during isolated coronary artery bypass graft surgery: insights from the ART (Arterial Revascularization Trial). J Am Heart Assoc 2018; 7:3.
Sander M, Spies CD, Martiny V, et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010; 14:R148.
Atasever AG, Eerens M, Van den Eynde R, et al. Efficacy and safety of aprotinin in paediatric cardiac surgery: a systematic review and meta-analysis. Eur J Anaesthesiol 2022; 39:352–367.
Zhang P, Lv H, Qi X, et al. Effect of ulinastatin on postoperative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up. J Cardiothorac Surg 2020; 15:98.
Lee SH, Lee SM, Kim CS, et al. Fibrinogen recovery and changes in fibrin-based clot firmness after cryoprecipitate administration in patients undergoing aortic surgery involving deep hypothermic circulatory arrest. Transfusion 2014; 54:1379–1387.
Doussau A, Perez P, Puntous M, et al. PLASMACARD Study Group. Fresh-frozen plasma transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort study. Transfusion 2014; 54:1114–1124.
Zhou SF, Estrera AL, Miller CC 3rd, et al. Analysis of autologous platelet-rich plasma during ascending and transverse aortic arch surgery. Ann Thorac Surg 2013; 95:1525–1530.
Blath L, Martens J, Rahe-Meyer N. Efficacy of platelet transfusion in cardiac surgery. Platelets 2022; 33:987–997.
Jin L, Ji HW. Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery. Chin Med J (Engl) 2015; 128:644–647.
Bignami E, Cattaneo M, Crescenzi G, et al. Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. Acta Anaesthesiol Scand 2016; 60:892–900.
Jahangirifard A, Razavi MR, Ahmadi ZH, et al. Effect of desmopressin on the amount of bleeding and transfusion requirements in patients undergoing heart transplant surgery. Basic Clin Pharmacol Toxicol 2017; 121:175–180.
Karkouti K, von Heymann C, Jespersen CM, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg 2013; 146:927–939.
Li J-Y, Gong J, Zhu F, et al. Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials. Anesth Analg 2018; 127:612–621.
Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117:41–51.
Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results. Interact Cardiovasc Thorac Surg 2019; 28:566–574.
Ranucci M, Jeppsson A, Baryshnikova E. Preoperative fibrinogen supplementation in cardiac surgery patients: an evaluation of different trigger values. Acta Anaesthesiol Scand 2015; 59:427–433.
Javaherforoosh Zadeh F, Janatmakan F, Soltanzadeh M, et al. Investigating the effect of fibrinogen injection on bleeding in coronary artery bypass surgery: a clinical trial. Anesth Pain Med 2019; 9:e92165.
Jeppsson A, Walden K, Roman-Emanuel C, et al. Preoperative supplementation with fibrinogen concentrate in cardiac surgery: a randomized controlled study. Br J Anaesth 2016; 116:208–214.
Walden K, Jeppsson A, Nasic S, et al. Fibrinogen concentrate to cardiac surgery patients with ongoing bleeding does not increase the risk of thromboembolic complications or death. Thromb Haemost 2020; 120:384–391.
Morrison GA, Koch J, Royds M, et al. Fibrinogen concentrate vs. fresh frozen plasma for the management of coagulopathy during thoraco-abdominal aortic aneurysm surgery: a pilot randomised controlled trial. Anaesthesia 2019; 74:180–189.
Callum J, Farkouh ME, Scales DC, et al. FIBRES Research Group. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES Randomized Clinical Trial. JAMA 2019; 322:1966–1976.
Galas FR, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg 2014; 148:1647–1655.
Downey LA, Andrews J, Hedlin H, et al. Fibrinogen concentrate as an alternative to cryoprecipitate in a postcardiopulmonary transfusion algorithm in infants undergoing cardiac surgery: a prospective randomized controlled trial. Anesth Analg 2020; 130:740–751.
Siemens K, Hunt BJ, Harris J, et al. Individualized, Intraoperative Dosing of Fibrinogen Concentrate for the Prevention of Bleeding in Neonatal and Infant Cardiac Surgery Using Cardiopulmonary Bypass (FIBCON): a phase 1b/2a randomized controlled trial. Circ Cardiovasc Interv 2020; 13:e009465.
Roman M, Biancari F, Ahmed AB, et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg 2019; 107:1275–1283.
Karkouti K, Bartoszko J, Grewal D, et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA Netw Open 2021; 4:e213936.
Green L, Roberts N, Cooper J, et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia 2021; 76:892–901.
Rao VK, Lobato RL, Bartlett B, et al. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28:1221–1226.
Abdel-Meguid ME. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Saudi J Anaesth 2013; 7:301–304.
Singh SP, Chauhan S, Choudhury M, et al. Recombinant activated factor VII in cardiac surgery: single-center experience. Asian Cardiovasc Thorac Ann 2014; 22:148–154.
Abu Hassan H, Rustom F, Bafaqih HA, et al. Effectiveness and safety of recombinant factor VII in pediatric cardiac surgery aged 13 years or less: a meta-analysis. Int J Health Sci 2020; 14:38–46.
Kurkluoglu M, Engle AM, Costello JP, et al. Single center experience on dosing and adverse events of recombinant factor seven use for bleeding after congenital heart surgery. J Saudi Heart Assoc 2015; 27:18–22.
Alfirevic A, Duncan A, You J, et al. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014; 98:618–624.
Downey L, Brown ML, Faraoni D, et al. Recombinant factor VIIa is associated with increased thrombotic complications in pediatric cardiac surgery patients. Anesth Analg 2017; 124:1431–1436.
Ranucci M, Baryshnikova E, Crapelli GB, et al. Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2013; 145:1393–1399.
Beattie GW, Jeffrey RR. Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery? Interact Cardiovasc Thorac Surg 2014; 18:117–120.
Clark KB, Kon ND, Hammon JW Jr, et al. Factor IX complex for the treatment of severe bleeding after cardiac surgery. J Cardiovasc Pharmacol 2013; 62:67–71.
Bolliger D, Tanaka KA. Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev 2013; 27:213–220.
Agarwal S, Johnson RI, Shaw M. Preoperative point-of-care platelet function testing in cardiac surgery. J Cardiothorac Vasc Anesth 2015; 29:333–341.
Nakayama Y, Nakajima Y, Tanaka KA, et al. Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery. Br J Anaesth 2015; 114:91–102.
Whitney G, Daves S, Hughes A, et al. Implementation of a transfusion algorithm to reduce blood product utilization in pediatric cardiac surgery. Paediatr Anaesth 2013; 23:639–646.
Karkouti K, McCluskey SA, Callum J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology 2015; 122:560–570.
Wozniak MJ, Abbasciano R, Monaghan A, et al. Systematic review and meta-analysis of diagnostic test accuracy studies evaluating point-of-care tests of coagulopathy in cardiac surgery. Transfus Med Rev 2021; 35:7–15.
Karkouti K, Callum J, Wijeysundera DN, et al. TACS Investigators. Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial. Circulation 2016; 134:1152–1162.
Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312–319.
Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531–547.
Krüger B, Renner T, Van Hemelrijck M, et al. The effect of hemoadsorption on rivaroxaban blood plasma concentration in emergency cardiac surgery. Indian J Thorac Cardiovasc Surg 2021; 37:680–683.
Poli EC, Alberio L, Bauer-Doerries A, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care 2019; 23:108.
Kogelmann K, Scheller M, Drüner M, et al. Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: a case series. J Intensive Care Soc 2020; 21:183–190.
Wang H, Gao X, Lv N, et al. Acute normovolemic hemodilution combined with controlled hypotension does not increase incidence of postoperative cognitive dysfunction in elderly spinal surgery patients. Int J Clin Exp Med 2017; 10:9526–9535.
Aritürk C, Ozgen ZS, Kilercik M, et al. Comparative effects of hemodilutional anemia and transfusion during cardiopulmonary bypass on acute kidney injury: a prospective randomized study. Heart Surg Forum 2015; 18:154.
Blaudszun G, Butchart A, Klein AA. Blood conservation in cardiac surgery. Transfus Med 2017; 28:168–180.
Li S, Liu Y, Zhu Y. Effect of acute normovolemic hemodilution on coronary artery bypass grafting: a systematic review and meta-analysis of 22 randomized trials. Int J Surg 2020; 83:131–139.
Mladinov D, Eudailey KW, Padilla LA, et al. Effects of acute normovolemic hemodilution on postcardiopulmonary bypass coagulation tests and allogeneic blood transfusion in thoracic aortic repair surgery: an observational cohort study. J Card Surg 2021; 36:4075–4082.
Licker M, Ellenberger C, Dierra J, et al. Cardioprotective effects of acute normovolemic hemodilution in patients undergoing coronary artery bypass surgery. Chest 2005; 128:838–847.
Licker M, Sierra J, Kalangos A, et al. Cardioprotective effects of acute normovolemic hemodilution in patients with severe aortic stenosis undergoing valve replacement. Transfusion 2007; 47:341–350.
Segal JB, Blasco-Colmenares E, Norris EJ, et al. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 2004; 44:632–644.
Rosberg B. Blood coagulation during and after normovolemic hemodilution in elective surgery. Ann Clin Res 1981; 13: (Suppl 33): 84–88.
Scott KJ, Shteamer JW, Szlam F, et al. Platelet function, but not thrombin generation, is impaired in acute normovolemic hemodilution (ANH) blood. J Clin Anesth 2019; 58:39–43.
Adam EH, Funke M, Zacharowski K, et al. Impact of intraoperative cell salvage on blood coagulation factor concentrations in patients undergoing cardiac surgery. Anesth Analg 2020; 130:1389–1395.
Al Khabori M, Al Riyami A, Siddiqi MS, et al. Impact of cell saver during cardiac surgery on blood transfusion requirements: a systematic review and meta-analysis. Vox Sang 2019; 114:553–565.
Bartoszko J, Karkouti K. Managing the coagulopathy associated with cardiopulmonary bypass. J Thromb Haemost 2021; 19:617–632.
Joshi RV, Wilkey AL, Blackwell JM, et al. Blood conservation and hemostasis in cardiac surgery: a survey of practice variation and adoption of evidence-based guidelines. Anesth Analg 2021; 133:104–114.
Neef V, Vo L, Herrmann E, et al. The association between intraoperative cell salvage and red blood cell transfusion in cardiac surgery - an observational study in a patient blood management centre. Anaesthesiol Intensive Ther 2021; 53:1–9.
Vieira SD, da Cunha Vieira Perini F, de Sousa LCB, et al. Autologous blood salvage in cardiac surgery: clinical evaluation, efficacy and levels of residual heparin. Hematol Transfus Cell Ther 2021; 43:1–8.
Bai SJ, Zeng B, Zhang L, et al. Autologous platelet-rich plasmapheresis in cardiovascular surgery: a narrative review. J Cardiothorac Vasc Anesth 2020; 34:1614–1621.
Grazioli A, Athale J, Tanaka K, et al. Perioperative applications of therapeutic plasma exchange in cardiac surgery: a narrative review. J Cardiothorac Vasc Anesth 2020; 34:3429–3443.
Moreno-Duarte I, Cooter M, Onwuemene OA, et al. Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia. Vox Sang 2021; 116:217–224.
Devereaux PJ, Marcucci M, Painter TW, et al. POISE-3 Investigators. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med 2022; 386:1986–1997.
Franchini M, Mengoli C, Marietta M, et al. Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfus 2018; 16:36–43.
Reale D, Andriolo L, Gursoy S, et al. Complications of tranexamic acid in orthopedic lower limb surgery: a meta-analysis of randomized controlled trials. Biomed Res Int 2021; 2021:6961540.
Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The efficacy of tranexamic acid in total hip arthroplasty: a network meta-analysis. J Arthroplasty 2018; 33:3083.e4–3089.e4.
He P, Zhang Z, Li Y, et al. Efficacy and safety of tranexamic acid in bilateral total knee replacement: a meta-analysis and systematic review. Med Sci Monit 2015; 21:3634–3642.
Huang F, Wu Y, Yin Z, et al. A systematic review and meta-analysis of the use of antifibrinolytic agents in total hip arthroplasty. Hip Int 2015; 25:502–509.
Jiang X, Ma XL, Ma JX. Efficiency and safety of intravenous tranexamic acid in simultaneous bilateral total knee arthroplasty: a systematic review and meta-analysis. Orthop Surg 2016; 8:285–293.
Dai WL, Zhou AG, Zhang H, et al. Most effective regimen of tranexamic acid for reducing bleeding and transfusions in primary total knee arthroplasty: a meta-analysis of randomized controlled trials. J Knee Surg 2018; 31:654–663.
Ma QM, Han GS, Li BW, et al. Effectiveness and safety of the use of antifibrinolytic agents in total-knee arthroplasty: a meta-analysis. Medicine (Baltimore) 2020; 99:e20214.
Xin WQ, Gao YL, Shen J, et al. Intravenous tranexamic acid reduces blood transfusions in revision total hip arthroplasty: a meta-analysis. J Comp Eff Res 2019; 8:917–928.
Wu Y, Yang T, Zeng Y, et al. Tranexamic acid reduces blood loss and transfusion requirements in primary simultaneous bilateral total knee arthroplasty: a meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 2017; 28:501–508.
Tian P, Liu WB, Li ZJ, et al. The efficacy and safety of tranexamic acid in revision total knee arthroplasty: a meta-analysis. BMC Musculoskelet Disord 2017; 18:273.
Weng K, Zhang X, Bi Q, et al. The effectiveness and safety of tranexamic acid in bilateral total knee arthroplasty: a meta-analysis. Medicine (Baltimore) 2016; 95:e4960.
Moskal JT, Capps SG. Meta-analysis of intravenous tranexamic acid in primary total hip arthroplasty. Orthopedics 2016; 39:e883–e892.
Yu X, Li W, Xu P, et al. Safety and efficacy of tranexamic acid in total knee arthroplasty. Med Sci Monit 2015; 21:3095–3103.
Wu Q, Zhang HA, Liu SL, et al. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol 2015; 25:525–541.
Wei Z, Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med 2015; 25:151–162.
Chen J, Li K, Chen Q, et al. Meta-analysis of the efficacy and safety of tranexamic acid in open spinal surgery [Chinese]. Chin J Tissue Eng Res 2020; 25:1458–1464.
Du Y, Feng C. The efficacy of tranexamic acid on blood loss from lumbar spinal fusion surgery: a meta-analysis of randomized controlled trials. World Neurosurg 2018; 119:E228–E234.
Fatima N, Barra ME, Roberts RJ, et al. Advances in surgical hemostasis: a comprehensive review and meta-analysis on topical tranexamic acid in spinal deformity surgery. Neurosurg Rev 2021; 44:163–175.
Hariharan D, Mammi M, Daniels K, et al. The safety and efficacy of tranexamic acid in adult spinal deformity surgery: a systematic review and meta-analysis. Drugs 2019; 79:1679–1688.
Hui S, Xu D, Ren Z, et al. Can tranexamic acid conserve blood and save operative time in spinal surgeries? A meta-analysis. Spine J 2018; 18:1325–1337.
Lu VM, Ho Y-T, Nambiar M, et al. The perioperative efficacy and safety of antifibrinolytics in adult spinal fusion surgery: a systematic review and meta-analysis. Spine 2018; 43:E949–E958.
Zhan F, Cheng J, Zou X, et al. Intraoperative intravenous application of tranexamic acid reduces perioperative bleeding in multilevel posterior spinal surgery: a meta-analysis [Chinese]. Chin J Tissue Eng Res 2020; 25:977–984.
Yuan L, Zeng Y, Chen ZQ, et al. Efficacy and safety of antifibrinolytic agents in spinal surgery: a network meta-analysis. Chin Med J (Engl) 2019; 132:577–588.
Zhang F, Wang K, Li FN, et al. Effectiveness of tranexamic acid in reducing blood loss in spinal surgery: a meta-analysis. BMC Musculoskelet Disord 2014; 15:448.
Zhao Y, Xi C, Xu W, et al. Role of tranexamic acid in blood loss control and blood transfusion management of patients undergoing multilevel spine surgery: a meta-analysis. Medicine (Baltimore) 2021; 100:e24678.
Haj-Younes B, Sivakumar BS, Wang M, et al. Tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Surg (Hong Kong) 2020; 28:2309499019887995.
Amer KM, Rehman S, Amer K, et al. Efficacy and safety of tranexamic acid in orthopaedic fracture surgery: a meta-analysis and systematic literature review. J Orthop Trauma 2017; 31:520–525.
Farrow LS, Smith TO, Ashcroft GP, et al. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol 2016; 82:1458–1470.
Xiao C, Zhang S, Long N, et al. Is intravenous tranexamic acid effective and safe during hip fracture surgery? An updated meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg 2019; 139:893–902.
Zhang P, He J, Fang Y, et al. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis. Medicine (United States) 2017; 96:e6940.
Watts CD, Houdek MT, Sems SA, et al. Tranexamic acid safely reduced blood loss in hemi- and total hip arthroplasty for acute femoral neck fracture: a randomized clinical trial. J Orthop Trauma 2017; 31:345–351.
Guo P, He Z, Wang Y, et al. Efficacy and safety of oral tranexamic acid in total knee arthroplasty: a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e0587.
Li H, Bai L, Li Y, et al. Oral tranexamic acid reduces blood loss in total-knee arthroplasty: a meta-analysis. Medicine 2018; 97:e12924.
Xu Y, Sun S, Feng Q, et al. The efficiency and safety of oral tranexamic acid in total hip arthroplasty: a meta-analysis. Medicine (Baltimore) 2019; 98:e17796.
Chen X, Zheng F, Zheng Z, et al. Oral vs intravenous tranexamic acid in total-knee arthroplasty and total hip arthroplasty: a systematic review and meta-analysis. Medicine 2019; 98:e15248.
Lu F, Sun X, Wang W, et al. What is the ideal route of administration of tranexamic acid in total knee arthroplasty? A meta-analysis based on randomized controlled trials. Ann Palliat Med 2021; 10:1880–1894.
Ye W, Liu Y, Liu WF, et al. Comparison of efficacy and safety between oral and intravenous administration of tranexamic acid for primary total knee/hip replacement: a meta-analysis of randomized controlled trial. J Orthop Surg Res 2020; 15:21.
Sun C, Zhang X, Chen L, et al. Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: a GRADE analysis and meta-analysis. Medicine 2020; 99:e22999.
Wang N, Xiong X, Xu L, et al. Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: a meta-analysis of randomized controlled trials. Medicine 2019; 98:e15279.
Wang L, Cao JG, Liu J. Comparison between oral and intravenous application of tranexamic acid for total hip arthroplasty: a meta-analysis. J Comp Eff Res 2019; 8:423–430.
Wang F, Zhao KC, Zhao MM, et al. The efficacy of oral versus intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. Medicine (Baltimore) 2018; 97:e12270.
Chen S, Wu K, Kong G, et al. The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis. BMC Musculoskelet Disord 2016; 17:81.
Zhang Y, Fu X, Liu WX, et al. Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. Orthopedics 2014; 37:e775–e782.
Zhao-Yu C, Yan G, Wei C, et al. Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature. Knee Surg Sports Traumatol Arthrosc 2014; 22:3181–3190.
Chen TP, Chen YM, Jiao JB, et al. Comparison of the effectiveness and safety of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials. J Orthop Surg Res 2017; 12:11.
Fu Y, Shi Z, Han B, et al. Comparing efficacy and safety of 2 methods of tranexamic acid administration in reducing blood loss following total knee arthroplasty: a meta-analysis. Medicine 2016; 95:e5583.
Hanna SA, Prasad A, Lee J, et al. Topical versus intravenous administration of tranexamic acid in primary total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Orthop Rev (Pavia) 2016; 8:6792.
Li J, Zhang Z, Chen J. Comparison of efficacy and safety of topical versus intravenous tranexamic acid in total hip arthroplasty: a meta-analysis. Medicine(Baltimore) 2016; 95:e4689.
Wang S, Gao X, An Y. Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Int Orthop 2017; 41:739–748.
Shin YS, Yoon JR, Lee HN, et al. Intravenous versus topical tranexamic acid administration in primary total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc 2017; 25:3585–3595.
Mi B, Liu G, Zhou W, et al. Intra-articular versus intravenous tranexamic acid application in total knee arthroplasty: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg 2017; 137:997–1009.
Meena S, Benazzo F, Dwivedi S, et al. Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. J Orthop Surg (Hong Kong) 2017; 25:739–748.
Zhang P, Liang Y, Chen P, et al. Intravenous versus topical tranexamic acid in primary total hip replacement: a meta-analysis. Medicine (Baltimore) 2016; 95:e5573.
Sun X, Dong Q, Zhang YG. Intravenous versus topical tranexamic acid in primary total hip replacement: a systemic review and meta-analysis. Int J Surg 2016; 32:10–18.
Li J, Liu R, Rai S, et al. Intra-articular vs. intravenous administration: a meta-analysis of tranexamic acid in primary total knee arthroplasty. J Orthop Surg Res 2020; 15:581.
Coelho M, Bastos C, Figueiredo J. Total knee arthroplasty: superiority of intra-articular tranexamic acid over intravenous and cell salvage as blood sparing strategy - a retrospective study. J Blood Med 2022; 13:75–82.
Li S, Chen B, Hua Z, et al. Comparative efficacy and safety of topical hemostatic agents in primary total knee arthroplasty: a network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2021; 100:e25087.
Wu Y, Zeng Y, Bao X, et al. Application of tranexamic acid and diluted epinephrine in primary total hip arthroplasty. Blood Coagul Fibrinolysis 2018; 29:451–457.
Wang Z, Zhang HJ. Comparative effectiveness and safety of tranexamic acid plus diluted epinephrine to control blood loss during total hip arthroplasty: a meta-analysis. J Orthop Surg Res 2018; 13:242.
Dengcheng H, Zhike W, Xuewei C. Intravenous, topical tranexamic acid alone or their combination in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Tissue Eng Res 2020; 25:948–956.
Li JF, Li H, Zhao H, et al. Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. J Orthop Surg Res 2017; 12:22.
Lin C, Qi Y, Jie L, et al. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: a meta-analysis. Medicine 2016; 95:e5344.
Liu X, Liu J, Sun G. A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: a meta-analysis. Int J Surg 2017; 41:34–43.
Zufferey PJ, Lanoiselee J, Chapelle C, et al. investigators of the PeriOpeRative Tranexamic acid in hip arthrOplasty (PORTO) Study. Intravenous tranexamic acid bolus plus infusion is not more effective than a single bolus in primary hip arthroplasty: a randomized controlled trial. Anesthesiology 2017; 127:413–422.
Chen R, Xiang Z, Gong M. The efficacy and safety of epsilon-aminocaproic acid for blood loss and transfusions in spinal deformity surgery: a meta-analysis. World Neurosurg 2019; 128:579.e1–586.e1.
Dong Q, Zhang Y, Sun X, et al. The effectiveness and safety of aminocaproic acid for reducing blood loss in total knee and hip arthroplasty: a meta-analysis. Int J Surg 2018; 52:156–163.
Li Y, Wang J. Efficacy of aminocaproic acid in the control of bleeding after total knee and hip arthroplasty: a systematic review and meta-analysis. Medicine 2019; 98:e14764.
Li YJ, Xu BS, Bai SP, et al. The efficacy of intravenous aminocaproic acid in primary total hip and knee arthroplasty: a meta-analysis. J Orthop Surg Res 2018; 13:89.
Liu Q, Geng P, Shi L, et al. Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: a systematic review and meta-analysis. Int J Surg 2018; 54:105–112.
Liu WB, Li GS, Shen P, et al. Comparison between epsilon-aminocaproic acid and tranexamic acid for total hip and knee arthroplasty: a meta-analysis. J Orthop Surg (Hong Kong) 2020; 28:2309499020959158.
Riaz O, Aqil A, Asmar S, et al. Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study. J Orthop Traumatol 2019; 20:28.
Cai DF, Fan QH, Zhong HH, et al. The effects of tourniquet use on blood loss in primary total knee arthroplasty for patients with osteoarthritis: a meta-analysis. J Orthop Surg Res 2019; 14:348.
Jiang FZ, Zhong HM, Hong YC, et al. Use of a tourniquet in total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Orthop Sci 2015; 20:110–123.
Li X, Yin L, Chen ZY, et al. The effect of tourniquet use in total knee arthroplasty: grading the evidence through an updated meta-analysis of randomized, controlled trials. Eur J Orthop Surg Traumatol 2014; 24:973–986.
Ahmed I, Chawla A, Underwood M, et al. Time to reconsider the routine use of tourniquets in total knee arthroplasty surgery. Bone Joint J 2021; 103-B:830–839.
Deng B, Hong H, Fan Y, et al. Efficacy and safety of tourniquet application in total knee arthroplasty and only at the time of cementing: a meta-analysis [Chinese]. Chin J Tissue Eng Res 2021; 25:2908–2914.
Lu C, Song M, Chen J, et al. Does tourniquet use affect the periprosthetic bone cement penetration in total knee arthroplasty? A meta-analysis. J Orthop Surg Res 2020; 15:602.
Migliorini F, Maffulli N, Aretini P, et al. Impact of tourniquet during knee arthroplasty: a bayesian network meta-analysis of peri-operative outcomes. Arch Orthop Trauma Surg 2021; 141:1007–1023.
Wang C, Zhou C, Qu H, et al. Comparison of tourniquet application only during cementation and long-duration tourniquet application in total knee arthroplasty: a meta-analysis. J Orthop Surg Res 2018; 13:216.
Huang Z, Ma J, Zhu Y, et al. Timing of tourniquet release in total knee arthroplasty. Orthopedics 2015; 38:445–451.
Kim TK, Bamne AB, Sim JA, et al. Is lower tourniquet pressure during total knee arthroplasty effective? A prospective randomized controlled trial. BMC Musculoskelet Disord 2019; 20:275.
Zhang P, Liang Y, He J, et al. Timing of tourniquet release in total knee arthroplasty: a meta-analysis. Medicine (Baltimore) 2017; 96:e6786.
Chaudhry EA, Aziz A, Faraz A, et al. Application of tourniquet does not influence early clinical outcomes after total knee arthroplasty. Cureus 2021; 13:e12435.
Huang Z, Xie X, Li L, et al. Intravenous and topical tranexamic acid alone are superior to tourniquet use for primary total knee arthroplasty: a prospective, randomized controlled trial. J Bone Joint Surg Am 2017; 99:2053–2061.
Zhang Y, Lang B, Zhao G, et al. Hemostatic effect of tourniquet combined with tranexamic acid in total knee arthroplasty: a network meta-analysis. J Orthop Surg Res 2020; 15:530.
Pan JK, Hong KH, Xie H, et al. The efficacy and safety of autologous blood transfusion drainage in patients undergoing total knee arthroplasty: a meta-analysis of 16 randomized controlled trials. BMC Musculoskelet Disord 2016; 17:452.
Hong KH, Pan JK, Yang WY, et al. Comparison between autologous blood transfusion drainage and closed-suction drainage/no drainage in total knee arthroplasty: a meta-analysis. BMC Musculoskelet Disord 2016; 17:142.
Ji W, Lin X, Zhang R, et al. Application of postoperative autotransfusion in total joint arthroplasty reduces allogeneic blood requirements: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 2017; 18:378.
Kelly EG, Cashman JP, Imran FH, et al. Systematic review and meta-analysis of closed suction drainage versus nondrainage in primary hip arthroplasty. Surg Technol Int 2014; 24:295–301.
Zan P, Wang W, Fan L, et al. Closed-suction drainage versus no drainage in total hip arthroplasty, a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2016; 9:725–735.
Fichman SG, Mäkinen TJ, Lozano B, et al. Closed suction drainage has no benefits in revision total hip arthroplasty: a randomized controlled trial. Int Orthop 2016; 40:453–457.
Bartosz P, Grzelecki D, Chaberek S, et al. A prospective randomized study, use of closed suction drainage after revision hip arthroplasty may lead to excessive blood loss. Sci Rep 2022; 12:881.
Lychagin AV, Rosenberg N, Gritsyuk AA. Evaluation of the potential complications of surgical wound drainage in primary total hip arthroplasty: a prospective controlled double-blind study. Hip Int 2021; 31:589–592.
Liu Y, Li Y, Miao J. Wound drains in posterior spinal surgery: a meta-analysis. J Orthop Surg Res 2016; 11:16.
Gubin AV, Prudnikova OG, Subramanyam KN, et al. Role of closed drain after multilevel posterior spinal surgery in adults: a randomised open-label superiority trial. Eur Spine J 2019; 28:146–154.
Migliorini F, Trivellas A, Eschweiler J, et al. Hospitalization length, surgical duration, and blood lost among the approaches for total hip arthroplasty: a Bayesian network meta-analysis. Musculoskelet Surg 2020; 104:257–266.
Awad ME, Farley BJ, Mostafa G, et al. Direct anterior approach has short-term functional benefit and higher resource requirements compared with the posterior approach in primary total hip arthroplasty: a meta-analysis of functional outcomes and cost. Bone Jt J 2021; 103B:1078–1087.
Cha Y, Yoo J-IL, Kim J-T, et al. Disadvantage during perioperative period of total hip arthroplasty using the direct anterior approach: a network meta-analysis. J Korean Med Sci 2020; 35:e111.
Chen W, Sun JN, Zhang Y, et al. Direct anterior versus posterolateral approaches for clinical outcomes after total hip arthroplasty: a systematic review and meta-analysis. J Orthop Surg Res 2020; 15:231.
Fu P, Shang W, Kang Z, et al. Efficacy of anterolateral minimally invasive approach versus traditional posterolateral approach in total hip arthroplasty: a meta-analysis [Chinese]. Chin J Tissue Eng Res 2021; 25:3409–3415.
Lei T, Qian H, Ye Z, et al. Is two-incision approach superior to the mini-posterior approach in total hip arthroplasty?: a meta-analysis. ANZ J Surg 2021; 91:E271–E279.
Mitchell MD, Betesh JS, Ahn J, et al. Transfusion thresholds for major orthopedic surgery: a systematic review and meta-analysis. J Arthroplasty 2017; 32:3815–3821.
Kim JL, Park JH, Han SB, et al. Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis. J Arthroplasty 2017; 32:320–325.
Everhart JS, Sojka JH, Mayerson JL, et al. Perioperative allogeneic red blood-cell transfusion associated with surgical site infection after total hip and knee arthroplasty. J Bone Joint Surg Am 2018; 100:288–294.
Brunskill SJ, Millette SL, Shokoohi A, et al. Red blood cell transfusion for people undergoing hip fracture surgery. Cochrane Database Syst Rev 2015; 4:CD009699.
Arirachakaran A, Amphansap T, Thanindratarn P, et al. Comparative outcome of PFNA, Gamma nails, PCCP, Medoff plate, LISS and dynamic hip screws for fixation in elderly trochanteric fractures: a systematic review and network meta-analysis of randomized controlled trials. Eur J Orthop Surg Traumatol 2017; 27:937–952.
Long H, Lin Z, Lu B, et al. Percutaneous compression plate versus dynamic hip screw for treatment of intertrochanteric hip fractures: a overview of systematic reviews and update meta-analysis of randomized controlled trials. Int J Surg 2016; 33 (Pt A):1–7.
Ju JB, Zhang PX, Jiang BG. Hip replacement as alternative to intramedullary nail in elderly patients with unstable intertrochanteric fracture: a systematic review and meta-analysis. Orthop Surg 2019; 11:745–754.
Junming C, Chen Y, Peilin H, et al. Hip arthroplasty versus proximal femoral nail antirotation for intertrochanteric fractures in older adults: a meta-analysis [Chinese]. Chin J Tissue Eng Res 2020; 25:1452–1457.
Chen J, Yue C, He P, et al. Comparison of clinical outcomes with hip replacement versus PFNA in the treatment of intertrochanteric fractures in the elderly: a systematic review and meta-analysis (PRISMA). Medicine 2021; 100:e24166.
El Madboh MS, Yonis L, Kabbash IA, et al. Proximal femoral plate, intramedullary nail fixation versus hip arthroplasty for unstable intertrochanteric femoral fracture in the elderly: a meta-analysis. Indian J Orthop 2022; 56:155–161.
Hao Z, Wang X, Zhang X. Comparing surgical interventions for intertrochanteric hip fracture by blood loss and operation time: a network meta-analysis. J Orthop Surg Res 2018; 13:157.
Li X, Luo J. Hemiarthroplasty compared to total hip arthroplasty for the treatment of femoral neck fractures: a systematic review and meta-analysis. J Orthop Surg Res 2021; 16:172.
Guan G, Cheng Z, Yin J, et al. Daytime versus after-hours surgery outcomes in hip fracture patients: a systematic review and meta-analysis. Aging Clin Exp Res 2020; 32:2427–2438.
Mullins B, Akehurst H, Slattery D, et al. Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. BMJ Open 2018; 8:e020625.
Bruckbauer M, Prexl O, Voelckel W, et al. Impact of direct oral anticoagulants in patients with hip fractures. J Orthop Trauma 2019; 33:e8–e13.
Neuman MD, Feng R, Carson JL, et al. REGAIN Investigators. Spinal anesthesia or general anesthesia for hip surgery in older adults. N Engl J Med 2021; 385:2025–2035.
HIP ATTACK Investigators. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet 2020; 395:698–708.
Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4:e258–e271.
Kaserer A, Casutt M, Sprengel K, et al. Comparison of two different coagulation algorithms on the use of allogenic blood products and coagulation factors in severely injured trauma patients: a retrospective, multicentre, observational study. Scand J Trauma Resusc Emerg Med 2018; 26:4.
Stein P, Kaserer A, Sprengel K, et al. Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia 2017; 72:1317–1326.
Gerlach R, Raabe A, Zimmermann M, et al. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000; 54:260–266.
Gerlach R, Tölle F, Raabe A, et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity. Stroke 2002; 33:1618–1623.
Korte W. FXIII in perioperative coagulation management. Best Pract Res Clin Anaesthesiol 2010; 24:85–93.
Korte WC, Szadkowski C, Gähler A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110:239–245.
Watanabe N, Yokoyama Y, Ebata T, et al. Clinical influence of preoperative factor XIII activity in patients undergoing pancreatoduodenectomy. HPB (Oxford) 2017; 19:972–977.
Chuliber FA, Schutz NP, Viñuales ES, et al. Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage. Blood Coagul Fibrinolysis 2020; 31:511–516.
Listyo S, Forrest E, Graf L, et al. The need for red cell support during non-cardiac surgery is associated to pre-transfusion levels of FXIII and the platelet count. J Clin Med 2020; 9:2456.
Wettstein P, Haeberli A, Stutz M, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99:1564–1569.
Adam EH, Meier J, Klee B, et al. Factor XIII activity in patients requiring surgical re-exploration for bleeding after elective cardiac surgery – a prospective case control study. J Crit Care 2020; 56:18–25.
Hildenbrand T, Idzko M, Panther E, et al. Treatment of nonhealing leg ulcers with fibrin-stabilizing factor XIII: a case report. Dermatol Surg 2002; 28:1098–1099.
Inoue H, Nishiyama N, Mizuguchi S, et al. Clinical value of exogenous factor XIII for prolonged air leak following pulmonary lobectomy: a case control study. BMC Surg 2014; 14:109–109.
Saito H, Fukushima R, Kobori O, et al. Marked and prolonged depression of Factor XIII after esophageal resection. Surg Today 1992; 22:201–206.
Carneiro JMGVdM, Alves J, Conde P, et al. Factor XIII-guided treatment algorithm reduces blood transfusion in burn surgery. Braz J Anesth 2018; 68:238–243.
Vanscheidt W, Kresse O, Hach-Wunderle V, et al. Leg ulcer patients: no decreased fibrinolytic response but white cell trapping after venous occlusion of the upper limb. Phlebology 1992; 7:92–96.
Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemost 1996; 22:445–450.
Takashima Y, Hashimoto S, Kamenaga T, et al. Recurrent hematomas following a revision total hip arthroplasty in acquired coagulation factor XIII deficiency. Case Rep Orthop 2019; 2019:4038963.
Kanda A, Kaneko K, Obayashi O, et al. The massive bleeding after the operation of hip joint surgery with the acquired haemorrhagic coagulation factor XIII(13) deficiency: two case reports. Case Rep Orthop 2013; 2013:473014.
Karimi M, Peyvandi F, Naderi M, et al. Factor XIII deficiency diagnosis: challenges and tools. Int J Lab Hematol 2018; 40:3–11.
Kleber C, Sablotzki A, Casu S, et al. The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing. Crit Care 2022; 26:69.
Carling MS, Zarhoud J, Jeppsson A, et al. Preoperative plasma fibrinogen concentration, factor XIII activity, perioperative bleeding, and transfusions in elective orthopaedic surgery: a prospective observational study. Thromb Res 2016; 139:142–147.
Tió MM, Sánchez-Etayo G, Bergé R, et al. Cost-effectiveness of postoperative cell salvage in total knee arthroplasty. Should we continue to recommend its use today? Rev Esp Anestesiol Reanim 2016; 63:444–450.
Duramaz A, Bilgili MG, Bayram B, et al. The role of intraoperative cell salvage system on blood management in major orthopedic surgeries: a cost-benefit analysis. Eur J Orthop Surg Traumatol 2018; 28:991–997.
Buget MI, Dikici F, Edipoğlu İS, et al. Two-year experience with cell salvage in total hip arthroplasty. Rev Bras Anestesiol 2016; 66:276–282.
van der Merwe M, Lightfoot NJ, Munro JT, et al. Intraoperative cell salvage use reduces the rate of perioperative allogenic blood transfusion in patients undergoing periacetabular osteotomy. J Hip Preserv Surg 2019; 6:277–283.
van Bodegom-Vos L, Voorn VM, So-Osman C, et al. Cell salvage in hip and knee arthroplasty: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2015; 97:1012–1021.
Dan M, Liu D, Martos SM, et al. Intra-operative blood salvage in total hip and knee arthroplasty. J Orthop Surg (Hong Kong) 2016; 24:204–208.
Margonis GA, Kim Y, Samaha M, et al. Blood loss and outcomes after resection of colorectal liver metastases. J Surg Res 2016; 202:473–480.
Costa Neves M, Neofytou K, Giakoustidis A, et al. Significant intraoperative blood loss predicts poor prognosis after hepatectomy following neoadjuvant chemotherapy for liver-only colorectal metastases. Ann Oncol 2016; 27: (Suppl 2): ii41–ii41.
Eeson G, Karanicolas PJ. Hemostasis and hepatic surgery. Surg Clin North Am 2016; 96:219–228.
Bodur MS, Tomas K, Topaloglu S, et al. Effects of intraoperative blood loss during liver resection on patients’ outcome: a single-center experience. Turk J Med Sci 2021; 51:1388–1395.
Moggia E, Rouse B, Simillis C, et al. Methods to decrease blood loss during liver resection: a network meta-analysis. Cochrane Database Syst Rev 2016; 10:CD010683.
Hughes MJ, Ventham NT, Harrison EM, et al. Central venous pressure and liver resection: a systematic review and meta-analysis. HPB (Oxford) 2015; 17:863–871.
Pan Y-X, Wang J-C, Lu X-Y, et al. Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: a double-blind randomized clinical trial. Surgery 2020; 167:933–941.
Gryspeerdt F, Khaldi MA, Bouchard C, et al. Impact of intraoperative hypovolemic phlebotomy on blood loss and perioperative transfusion in patients undergoing hepatectomy for cancer. HPB 2019; 21: (Suppl 1): S72–S72.
Baker L, Bennett S, Rekman J, et al. Hypovolemic phlebotomy in liver surgery is associated with decreased red blood cell transfusion. HPB (Oxford) 2019; 21:757–764.
Martel G, Wherrett C, Rekman J, et al. Safety and feasibility of phlebotomy with controlled hypovolemia to prevent blood loss in major hepatic resections. HPB 2016; 18:e232–e232.
Al Khaldi M, Gryspeerdt F, Carrier FM, et al. Effect of intraoperative hypovolemic phlebotomy on transfusion and clinical outcomes in patients undergoing hepatectomy: a retrospective cohort study. Can J Anaesth 2021; 68:980–990.
Rekman J, Wherrett C, Bennett S, et al. Safety and feasibility of phlebotomy with controlled hypovolemia to minimize blood loss in liver resections. Surgery 2017; 161:650–657.
Martel G, Baker L, Wherrett C, et al. Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility. Brit J Surg 2020; 107:812–823.
Ryckx A, Christiaens C, Clarysse M, et al. Central venous pressure drop after hypovolemic phlebotomy is a strong independent predictor of intraoperative blood loss during liver resection. Ann Surg Oncol 2017; 24:1367–1375.
Park L, Gilbert R, Baker L, et al. The safety and efficacy of hypovolemic phlebotomy on blood loss and transfusion in liver surgery: a systematic review and meta-analysis. HPB (Oxford) 2020; 22:340–350.
Imamura T, Yamamoto Y, Sugiura T, et al. Infrahepatic inferior vena cava semi-clamping can reduce blood loss during hepatic resection but still requires monitoring to avoid acute kidney injury. World J Surg 2019; 43:2038–2047.
Junrungsee S, Suwannikom K, Tiyaprasertkul W, et al. Efficacy and safety of infrahepatic inferior vena cava clamping under controlled central venous pressure for reducing blood loss during hepatectomy: a randomized controlled trial. J Hepatobiliary Pancreat Sci 2021; 27:27–27.
Suwannikom K, Junrungsee S, Tiyaprasertkul W, et al. Infrahepatic inferior vena cava (IVC) occlusion technique for reducing blood loss during hepatectomy: a randomized controlled trial. HPB 2018; 20: (Suppl 2): S174–S174.
Leeratanakachorn N, Luvira V, Tipwaratorn T, et al. Infrahepatic inferior vena cava clamping reduces blood loss during liver transection for cholangiocarcinoma. Int J Hepatol 2021; 2021:1625717.
Ueno M, Kawai M, Hayami S, et al. Partial clamping of the infrahepatic inferior vena cava for blood loss reduction during anatomic liver resection: a prospective, randomized, controlled trial. Surgery 2017; 161:1502–1513.
Xiao LK, Huang P, Wu K, et al. Effect of infrahepatic inferior vena cava partial clamping on central venous pressure and intraoperative blood loss during laparoscopic hepatectomy. Surg Endosc 2021; 35:2773–2780.
Zhang W, Dong H, Li C, et al. Infrahepatic inferior vena cava clamping reduce blood loss during laparoscopic hepatectomy. HPB 2016; 18:e268–e269.
Zhou Y, Zhang Z, Wan T. Effect of infrahepatic inferior vena cava clamping on bleeding during hepatic resection: a meta-analysis. Asian J Surg 2018; 41:523–529.
Choi SS, Jun IG, Cho SS, et al. Effect of stroke volume variation-directed fluid management on blood loss during living-donor right hepatectomy: a randomised controlled study. Anaesthesia 2015; 70:1250–1258.
Seo H, Jun I-G, Ha T-Y, et al. High stroke volume variation method by mannitol administration can decrease blood loss during donor hepatectomy. Medicine (Baltimore) 2016; 95:e2328.
Shih TH, Tsou YH, Huang CJ, et al. The correlation between CVP and SVV and intraoperative minimal blood loss in living donor hepatectomy. Transplant Proc 2018; 50:2661–2663.
Saito R, Amemiya H, Hosomura N, et al. Stroke volume variation monitoring to minimize blood loss in hepatocellular carcinoma resection. Anticancer Res 2021; 41:409–415.
Gao X, Xiong Y, Huang J, et al. The effect of mechanical ventilation with low tidal volume on blood loss during laparoscopic liver resection: a randomized controlled trial. Anesth Analg 2021; 132:1033–1041.
Iguchi T, Ikegami T, Fujiyoshi T, et al. Low positive airway pressure without positive end-expiratory pressure decreases blood loss during hepatectomy in living liver donors. Dig Surg 2017; 34:192–196.
Abbas MS, Mohamed KS, Ibraheim OA, et al. Effects of terlipressin infusion on blood loss and transfusion needs during liver resection: a randomised trial. Acta Anaesthesiol Scand 2019; 63:34–39.
Mahdy MM, Abbas MS, Kamel EZ, et al. Effects of terlipressin infusion during hepatobiliary surgery on systemic and splanchnic haemodynamics, renal function and blood loss: a double-blind, randomized clinical trial. BMC Anesthesiol 2019; 19:106.
Huo YR, Shiraev T, Alzahrani N, et al. Reducing inflow occlusion, occlusion duration and blood loss during hepatic resections. ANZ J Surg 2018; 88:E25–E29.
Gelli M, Allard MA, Farges O, et al. Association de Chirurgie Hepato-Biliaire et de Transplantation Hépatique (ACHBT)-French Hepatectomy Study Group. Use of aspirin and bleeding-related complications after hepatic resection. Brit J Surg 2018; 105:429–438.
Naito S, Fujikawa T, Hasegawa S. Impact of preoperative aspirin continuation on bleeding complications during or after liver resection: propensity score-matched analysis. J Hepatobiliary Pancreat Sci 2020; 27:830–838.
Rana A, Petrowsky H, Hong JC, et al. Blood transfusion requirement during liver transplantation is an important risk factor for mortality. J Am Coll Surg 2013; 216:902–907.
Cywinski JB, Alster JM, Miller C, et al. Prediction of intraoperative transfusion requirements during orthotopic liver transplantation and the influence on postoperative patient survival. Anesth Analg 2014; 118:428–437.
Kumar Srivastava P, Agarwal A, Jha A, et al. Intraoperative blood loss during living donor liver transplantation: an analysis of 950 recipients at a single centre. Transplantation 2019; 103: (8 Suppl 1): 106–106.
Kornberg A, Witt U, Kornberg J, et al. Prognostic impact of intraoperative blood loss in liver transplant patients with advanced hepatocellular carcinoma. Anticancer Res 2016; 36:5355–5364.
Liu B, Teng F, Fu H, et al. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 2015; 15:138–138.
Arshad F, Lisman T, Porte RJ. Blood markers of portal hypertension are associated with blood loss and transfusion requirements during orthotopic liver transplantation. Semin Thromb Hemost 2020; 46:751–756.
Lekerika N, Gutiérrez Rico RM, Arco Vázquez J, et al. Predicting fluid responsiveness in patients undergoing orthotopic liver transplantation: effects on intraoperative blood transfusion and postoperative complications. Transplant Proc 2014; 46:3087–3091.
Abeysundara L, Mallett SV, Clevenger B. Point-of-care testing in liver disease and liver surgery. Semin Thromb Hemost 2017; 43:407–415.
Massicotte L, Thibeault L, Roy A. Classical notions of coagulation revisited in relation with blood losses, transfusion rate for 700 consecutive liver transplantations. Semin Thromb Hemost 2015; 41:538–546.
Massicotte L, Carrier FM, Denault AY, et al. Development of a predictive model for blood transfusions and bleeding during liver transplantation: an observational cohort study. J Cardiothorac Vasc Anesth 2018; 32:1722–1730.
Starczewska MH, Giercuszkiewicz D, Niewinski G, et al. Perioperative bleeding in patients undergoing liver transplantation. Anestezjol Intens Ter 2016; 48:34–40.
Pratschke S, Rauch A, Albertsmeier M, et al. Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce intraoperative blood loss and improve postoperative transaminases and renal function: a meta-analysis. World J Surg 2016; 40:2988–2998.
Goerlinger K, Perez-Ferrer A, Dirkmann D, et al. The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management. Korean J Anesth 2019; 72:297–322.
Saner FH, Kirchner C. Monitoring and treatment of coagulation disorders in end-stage liver disease. Visc Med 2016; 32:241–248.
Tripodi A, Primignani M, Mannucci PM, et al. Changing concepts of cirrhotic coagulopathy. Am J Gastroenterol 2017; 112:274–281.
Kovalic AJ, Majeed CN, Samji NS, et al. Systematic review with meta-analysis: abnormalities in the International Normalised Ratio (INR) do not correlate with periprocedural bleeding events among patients with cirrhosis. Aliment Pharmacol Ther 2020; 52:1298–1310.
Mallett SV, Sugavanam A, Krzanicki DA, et al. Alterations in coagulation following major liver resection. Anaesthesia 2016; 71:657–668.
Bihari C, Patil A, Shasthry SM, et al. Viscoelastic test-based bleeding risk score reliably predicts coagulopathic bleeding in decompensated cirrhosis and ACLF patients. Hepatol Int 2020; 14:597–608.
Sabate A, Blasi A, Costa M, et al. Assessment of rotational thromboelastometry for the prediction of red blood cell requirements in orthotopic liver transplantation. Minerva Anestesiol 2018; 84:447–454.
Fayed N, Mourad W, Yassen K, et al. Preoperative thromboelastometry as a predictor of transfusion requirements during adult living donor liver transplantation. Transfus Med Hemother 2015; 42:99–108.
Tafur LA, Taura P, Blasi A, et al. Rotation thromboelastometry velocity curve predicts blood loss during liver transplantation. Br J Anaesth 2016; 117:741–748.
De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63:566–573.
Garrigue D, Albaladejo P, Belisle S, et al. Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: what role for which indication in bleeding situations? Anesthesie et Reanim 2018; 4:452–464.
Haas T, Gorlinger K, Grassetto A, et al. Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. Minerva Anestesiol 2014; 80:1320–1335.
Zamper RPC, Amorim TC, Costa L, et al. The role of thromboelastometry in the assessment and treatment of coagulopathy in liver transplant patients. Einstein 2017; 15:243–246.
Schumacher C, Eismann H, Sieg L, et al. Use of rotational thromboelastometry in liver transplantation is associated with reduced transfusion requirements. Exp Clin Transplant 2019; 17:222–230.
Bonnet A, Gilquin N, Steer N, et al. The use of a thromboelastometry-based algorithm reduces the need for blood product transfusion during orthotopic liver transplantation: a randomised controlled study. Eur J Anaesthesiol 2019; 36:825–833.
Scarlatescu E, Tomescu DR. The effect of a viscoelastic-based bleeding algorithm implementation on blood products use in adult liver transplant patients: a before-after study. Res Pract Thromb Haemost 2019; 3: (Suppl): 55–56.
Smart L, Mumtaz K, Scharpf D, et al. Rotational thromboelastometry or conventional coagulation tests in liver transplantation: comparing blood loss, transfusions, and cost. Ann Hepatol 2017; 16:916–923.
Leon-Justel A, Noval-Padillo JA, Alvarez-Rios AI, et al. Point-of-care haemostasis monitoring during liver transplantation reduces transfusion requirements and improves patient outcome. Clin Chim Acta 2015; 446:277–283.
Zamper RPC, Amorim TC, Queiroz VNF, et al. Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study. BMC Anesthesiol 2018; 18:198.
De Pietri L, Ragusa F, Deleuterio A, et al. Reduced transfusion during OLT by POC coagulation management and TEG functional fibrinogen: a retrospective observational study. Transplant Direct 2015; 2:e49.
Dotsch TM, Dirkmann D, Bezinover D, et al. Assessment of standard laboratory tests and rotational thromboelastometry for the prediction of postoperative bleeding in liver transplantation. Br J Anaesth 2017; 119:402–410.
Carrier FM, Denault AY, Nozza A, et al. Association between intraoperative rotational thromboelastometry or conventional coagulation tests and bleeding in liver transplantation: an observational exploratory study. Anaesth Crit Care Pain Med 2020; 39:765–770.
Kamel Y, Hassanin A, Ahmed AR, et al. Perioperative thromboelastometry for adult living donor liver transplant recipients with a tendency to hypercoagulability: a prospective observational cohort study. Transfus Med Hemother 2018; 45:404–412.
Blasi A, Molina V, Sanchez-Cabús S, et al. Prediction of thromboembolic complications after liver resection for cholangiocarcinoma: is there a place for thromboelastometry? Blood Coagul Fibrinolysis 2018; 29:61–66.
Zanetto A, Senzolo M, Vitale A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49:440–445.
Roullet S, Freyburger G, Labrouche S, et al. Hyperfibrinolysis during liver transplantation is associated with bleeding. Thromb Haemost 2015; 113:1145–1148.
Poon KS, Chen CC, Thorat A, et al. Fibrinolysis after reperfusion of liver graft. Acta Anaesthesiol Taiwan 2015; 53:41–43.
Badenoch A, Sharma A, Gower S, et al. The effectiveness and safety of tranexamic acid in orthotopic liver transplantation clinical practice: a propensity score matched cohort study. Transplantation 2017; 101:1658–1665.
Schofield N, Sugavanam A, Thompson K, et al. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. Liver Transpl 2014; 20:584–590.
Bezinover D, Dirkmann D, Findlay J, et al. Perioperative coagulation management in liver transplant recipients. Transplantation 2018; 102:578–592.
Görlinger K, Sakai T, Dirkmann D. Teruya J, et al. Bleeding related to liver transplant. Management of bleeding patients . Cham: Springer International Publishing; 2021. 339–359.
Roullet S, de Maistre E, Ickx B, et al. GIHP. Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: what role for which indication in bleeding situations? Anaesth Critical Care Pain Med 2019; 38:539–548.
Drebes A, de Vos M, Gill S, et al. Prothrombin complex concentrates for coagulopathy in liver disease: single-center, clinical experience in 105 patients. Hepatol Commun 2019; 3:513–524.
Srivastava P, Agarwal A, Jha A, et al. Utility of prothrombin complex concentrate as first-line treatment modality for coagulopathy in patients undergoing liver transplantation: a propensity score-matched study. Int J Surg 2020; 75: (Suppl): S5–S15.
Kirchner C, Dirkmann D, Treckmann JW, et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54:2760–2768.
Hartmann M, Walde C, Dirkmann D, et al. Safety of coagulation factor concentrates guided by ROTEM™-analyses in liver transplantation: results from 372 procedures. BMC Anesthesiol 2019; 19:97.
Saner FH, Abeysundara L, Hartmann M, et al. Rational approach to transfusion in liver transplantation. Minerva Anestesiol 2018; 84:378–388.
Abuelkasem E, Hasan S, Mazzeffi MA, et al. Reduced requirement for prothrombin complex concentrate for the restoration of thrombin generation in plasma from liver transplant recipients. Anesth Analg 2017; 125:609–615.
Chow JH, Lee K, Abuelkasem E, et al. Coagulation management during liver transplantation: use of fibrinogen concentrate, recombinant activated factor VII, prothrombin complex concentrate, and antifibrinolytics. Semin Cardiothorac Vasc Anesth 2017; 22:164–173.
Costa M, Dalmau A, Sabate A, et al. Low plasma fibrinogen levels and blood product transfusion in liver transplantation. Minerva Anestesiol 2014; 80:568–573.
Sabate A, Gutierrez R, Beltran J, et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Transplant 2016; 16:2421–2429.
Biancofiore G, Blasi A, De Boer MT, et al. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE). Minerva Anestesiol 2019; 85:782–798.
Bansal A, Arora A. A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World J Urol 2017; 35:1233–1240.
Siddiq A, Khalid S, Mithani H, et al. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. J Urol Surg 2017; 4:195–201.
Gupta A, Priyadarshi S, Vyas N, et al. Efficacy of tranexamic acid in decreasing primary hemorrhage in transurethral resection of the prostate: a novel combination of intravenous and topical approach. Urol Ann 2021; 13:238–242.
Meng QQ, Pan N, Xiong JY, et al. Tranexamic acid is beneficial for reducing perioperative blood loss in transurethral resection of the prostate. Exp Ther Med 2019; 17:943–947.
Philip A, Vicknesh C, Mugialan P, et al. Patching the plumbing: the role of tranexamic acid in reducing postoperative bleeding following transurethral resection of prostate (TURP). BJU Int 2018; 122: (Suppl 4): 14–15.
Soundarya G, Chengalvarayan G, Vezhaventhan G, et al. The effectiveness of tranexamic acid in reducing bleeding related to trans urethral resection–of prostate - a prospective study. Indian J Urol 2017; 33:72–77.
Pourfakhr P, Gatavi E, Gooran S, et al. Local administration of tranexamic acid during prostatectomy surgery: effects on reducing the amount of bleeding. Nephrourol Mon 2016; 8:e40409.
Longo MA, Cavalheiro BT, de Oliveira Filho GR. Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. J Clin Anesth 2018; 48:32–38.
Mina SH, Garcia-Perdomo HA. Effectiveness of tranexamic acid for decreasing bleeding in prostate surgery: a systematic review and meta-analysis. Cent European J Urol 2018; 71:72–77.
Soleimani M, Masoumi N, Nooraei N, et al. The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double-blind placebo-controlled and randomized study. J Thromb Haemost 2017; 15:255–262.
Sare A, Kothari P, Cieslak JA 3rd, et al. Perioperative blood loss after preoperative prostatic artery embolization in patients undergoing simple prostatectomy: a propensity score matched study. J Vasc Interv Radiol 2021; 29:29–29.
Shin MG, Kim KY, Han Y-M, et al. Single-center retrospective study of preoperative prostatic artery embolization with the use of gelatin sponge: initial experience and influence for blood loss in prostate surgery. J Vasc Interv Radiol 2019; 30:655–660.
Floortje van Oosten A, Smits FJ, van den Heuvel DAF, et al. Diagnosis and management of postpancreatectomy hemorrhage: a systematic review and meta-analysis. HPB 2019; 21:953–961.
Robertson HF, Maccabe TA, Strickland A, et al. A systematic review of the management of postpancreatectomy haemorrhage. Brit J Surg 2019; 106: (Suppl 7): 23–123.
Wang WG, Zhang Y, Wang L, et al. Postpancreatectomy hemorrhage after pancreatoduodenectomy incidence, risk factors, and treatment in 1056 cases. Pancreatology 2016; 16:S12–S12.
Zhang C, Li A, Luo T, et al. Strategy and management of severe hemorrhage complicating pancreatitis and postpancreatectomy. Diagn Interv Radiol 2019; 25:81–89.
Zarzavadjian Le Bian A, Fuks D, Montali F, et al. Predicting the severity of pancreatic fistula after pancreaticoduodenectomy: overweight and blood loss as independent risk factors: retrospective analysis of 277 patients. Surg Infect (Larchmt) 2019; 20:486–491.
Le Bian AZ, Fuks D, Montali F, et al. Predicting the severity of pancreatic fistula after pancreaticoduodenectomy: overweight and blood loss as independent risk factors: retrospective analysis of 277 patients. Surg Infect (Larchmt) 2019; 20:486–491.
Tamagawa H, Aoyama T, Yamamoto N, et al. The impact of intraoperative blood loss on the survival of patients with stage II/III pancreatic cancer. In Vivo 2020; 34:1469–1474.
Tingstedt B, Lindell G, Keussen I, et al. Hemorrhage after major pancreatic resection: incidence, risk factors, management, and outcome. Scand J Surg 2017; 106:47–53.
Trudeau MT, Casciani F, Maggino L, et al. Pancreas Fistula Study Group. The influence of intraoperative blood loss on fistula development following pancreatoduodenectomy. Ann Surg 2020; 12:12–12.
Ishida J, Fukumoto T, Kido M, et al. Hemorrhagic and thromboembolic complications after hepato-biliary-pancreatic surgery in patients receiving antithrombotic therapy. Dig Surg 2017; 34:114–124.
Hayashi H, Morikawa T, Mizuma M, et al. Chemical thromboprophylaxis decrease the risk of pulmonary embolism and did not increase the risk of major hemorrhage after hepatobiliary-pancreatic surgery. HPB 2015; 17:147–148.
Ivanics T, Shubert CR, Muaddi H, et al. Blood cell salvage and autotransfusion does not worsen oncologic outcomes following liver transplantation with incidental hepatocellular carcinoma: a propensity score-matched analysis. Ann Surg Oncol 2021; 28:6816–6825.
Han S, Kim G, Ko JS, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg 2016; 264:339–343.
Araujo RL, Pantanali CA, Haddad L, et al. Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence? World J Gastrointest Surg 2016; 8:161–168.
Sutton TL, Pasko J, Kelly G, et al. Intraoperative autologous transfusion and oncologic outcomes in liver transplantation for hepatocellular carcinoma: a propensity matched analysis. HPB (Oxford) 2022; 24:379–385.
Nutu OA, Sneiders D, Mirza D, et al. Safety of intra-operative blood salvage during liver transplantation in patients with hepatocellular carcinoma, a propensity score-matched survival analysis. Transpl Int 2021; 34:2887–2894.
Pinto MA, Grezzana-Filho TJM, Chedid AD, et al. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma. Langenbecks Arch Surg 2021; 406:67–74.
Xu J, Kinnear N, Johns Putra L. Safety, efficacy and cost of intra-operative cell salvage during open radical prostatectomy. Transl Androl Urol 2021; 10:1241–1249.
Myrga JM, Ayyash OM, Bandari J, et al. The safety and short-term outcomes of leukocyte depleted autologous transfusions during radical cystectomy. Urology 2020; 135:106–110.
Kinnear N, Hua L, Heijkoop B, et al. The impact of intra-operative cell salvage during open nephrectomy. Asian J Urol 2019; 6:346–352.
Kang R, Seath BE, Huang V, et al. Impact of autologous blood transfusion on survival and recurrence among patients undergoing partial hepatectomy for colorectal cancer liver metastases. J Am Coll Surg 2019; 228:902–908.
Frietsch T, Steinbicker AU, Horn A, et al. Safety of intraoperative cell salvage in cancer surgery: an updated meta-analysis of the current literature. Transfus Med Hemother 2022; 49:143–157.
Roccarina D, Best LM, Freeman SC, et al. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2021; 4:CD013121.
Sharma M, Singh S, Desai V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology 2019; 69:1657–1675.
Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep 2020; 2:100063.
Yoo JJ, Kim SG, Kim YS, et al. Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: propensity score matching analysis. Medicine (Baltimore) 2020; 99:e18913.
Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol 2021; 116:899–917.
Siau K, Hearnshaw S, Stanley AJ, et al. British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding. Frontline Gastroenterol 2020; 11:311–323.
Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ 2019; 364:l536–l536.
Habib S, Boyer TD. TIPS in variceal bleeding: new and old indications. Curr Hepat Rep 2014; 13:218–223.
Mallet M, Rudler M, Thabut D. Variceal bleeding in cirrhotic patients. Gastroenterol Rep 2017; 5:185–192.
Bucsics T, Schoder M, Goeschl N, et al. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Dig Liver Dis 2017; 49:1360–1367.
Deltenre P, Trepo E, Rudler M, et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials. Eur J Gastroenterol Hepatol 2015; 27:e1–e9.
Dunne PDJ, Sinha R, Stanley AJ, et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Aliment Pharmacol Ther 2020; 52:98–106.
Hernandez-Gea V, Procopet B, Giraldez A, et al. International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology 2019; 69:282–293.
Garbuzenko DV. Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding. Curr Med Res Opin 2016; 32:467–475.
Halabi SA, Sawas T, Sadat B, et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2016; 31:1519–1526.
Lv Y, Yang Z, He C, et al. Early TIPS with covered stent versus standard treatment for acute variceal bleeding among patients with advanced cirrhosis: a randomised controlled trial. J Hepatol 2019; 70:e18–e19.
Conejo I, Guardascione MA, Tandon P, et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding. Clin Gastroenterol Hepatol 2018; 16:132.e8–139.e8.
Li S, Zhang C, Lin LL, et al. Early-TIPS versus current standard therapy for acute variceal bleeding in cirrhosis patients: a systemic review with meta-analysis. Front Pharmacol 2020; 11:603.
Nicoara-Farcau O, Han G, Rudler M, et al. Preemptive TIPS Individual Data Metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. Gastroenterology 2021; 160:193.e10–205.e10.
Zhou GP, Jiang YZ, Sun LY, et al. Early transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a systematic review and meta-analysis. Eur Radiol 2021; 31:5390–5399.
Njei B, Laine L. Early use of tips and outcomes in patients with cirrhosis and acute esophageal variceal bleeding: analysis of the U.S. nationwide inpatient sample (NIS) database, 2000-2010 ACG fellows-in-training award. Am J Gastroenterol 2015; 110:S870–S870.
Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroenterol Hepatol 2017; 32:852–858.
Niekamp A, Kuban JD, Lee SR, et al. Transjugular intrahepatic portosystemic shunts reduce variceal bleeding and improve survival in patients with cirrhosis: a population-based analysis. J Vasc Interv Radiol 2020; 31:1382.e2–1391.e2.
Zhu Y, Wang X, Xi X, et al. Emergency transjugular intrahepatic portosystemic shunt: an effective and safe treatment for uncontrolled variceal bleeding. J Gastrointest Surg 2019; 23:2193–2200.
Brand M, Prodehl L, Ede CJ. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis. Cochrane Database Syst Rev 2018; 10:CD001023.
Albillos A, Tejedor M. Secondary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 2014; 18:359–370.
Bhutta AQ, Garcia-Tsao G. The role of medical therapy for variceal bleeding. Gastrointest Endosc Clin N Am 2015; 25:479–490.
Albillos A, Zamora J, Martinez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology 2017; 66:1219–1231.
Korsic S, Stabuc B, Skok P, et al. TIPS vs. endoscopic treatment for prevention of recurrent variceal bleeding: a long-term follow-up of 126 patients. Radiol Oncol 2021; 55:164–171.
Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology 2016; 63:581–589.
Luo X, Wang Z, Tsauo J, et al. Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology 2015; 276:286–293.
Zhang M, Wang G, Zhao L, et al. Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG. Scand J Gastroenterol 2016; 51:1502–1506.
Plaz Torres MC, Best LM, Freeman SC, et al. Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2021; 3:CD013122.
Zhang Q, Liu H, Chang Z, et al. Nonsurgical secondary prophylaxis of esophageal variceal bleeding for cirrhotic patients: a systematic review and network meta-analysis. J Dig Dis 2020; 21: (Suppl 1): 37–38.
Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality postendoscopic variceal band ligation in cirrhotic patients. Liver Int 2018; 38:1253–1262.
Chiu PW, Joeng HK, Choi CL, et al. High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial. Endoscopy 2016; 48:717–722.
Chiu PWY. Endoscopic management of peptic ulcer bleeding: recent advances. Clin Endosc 2019; 52:416–418.
Lau JYW, Pittayanon R, Wong KT, et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut 2019; 68:796–803.
Mullady DK, Wang AY, Waschke KA. AGA Clinical Practice Update on endoscopic therapies for non-variceal upper gastrointestinal bleeding: expert review. Gastroenterology 2020; 159:1120–1128.
Nelms DW, Pelaez CA. The acute upper gastrointestinal bleed. Surg Clin North Am 2018; 98:1047–1057.
Darmon I, Rebibo L, Diouf M, et al. Management of bleeding peptic duodenal ulcer refractory to endoscopic treatment: surgery or transcatheter arterial embolization as first-line therapy? A retrospective single-center study and systematic review. Eur J Trauma Emerg Surg 2020; 46:1025–1035.
Kate V, Kola GST, Mohsina S, et al. Restrictive vs. liberal transfusions strategy in patients with upper gastrointestinal bleeding: a randomized controlled trial. Gastroenterology 2018; 154:S700–S701.
Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015; 386:137–144.
Rodrigues A, Carrilho A, Almeida N, et al. Interventional algorithm in gastrointestinal bleeding-an expert consensus multimodal approach based on a multidisciplinary team. Clin Appl Thromb Hemost 2020; 26:1076029620931943.
Mohanty A, Kapuria D, Canakis A, et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: results from a multicentre cohort study. Liver Int 2021; 41:1901–1908.
HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395:1927–1936.
Karadas A, Dogan NO, Pinar SG, et al. A randomized controlled trial of the effects of local tranexamic acid on mortality, rebleeding, and recurrent endoscopy need in patients with upper gastrointestinal hemorrhage. Eur J Gastroenterol Hepatol 2020; 32:26–31.
Saidi H, Shojaie S, Ghavami Y, et al. Role of intra-gastric tranexamic acid in management of acute upper gastrointestinal bleeding. IIOAB J 2017; 8:76–81.
Khodadoostan M, Shahbazi A, Shavakhi A. Is topical tranexamic acid effective in upper GI bleeding? United Eur Gastroenterol J 2018; 6: (8 Suppl): A497–A497.
Zhou X, Zhang C, Wang Y, et al. Preoperative acute normovolemic hemodilution for minimizing allogeneic blood transfusion: a meta-analysis. Anesth Analg 2015; 121:1443–1455.
Tanner EJ, Filippova OT, Gardner GJ, et al. A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol 2018; 151:433–437.
Boerner T, Tanner E, Filippova O, et al. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: a Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol 2021; 160:51–55.
Saito J, Masui K, Noguchi S, et al. The efficacy of acute normovolemic hemodilution for preventing perioperative allogeneic blood transfusion in gynecological cancer patients. J Clin Anesth 2020; 60:42–43.
Frietsch T, Steinbicker AU, Hackbusch M, et al. Safety of cell salvage in tumor surgery: systematic review with meta-analysis. Anaesthesist 2020; 69:331–351.
Sirotich E, Jamula E, Wang AY, et al. Impact of iron supplementation on patient outcomes in women undergoing gynecological procedures: systematic review and meta-analysis of randomized trials. Blood 2019; 134:59.
Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 2016; 3:e415–e425.
Ye Z, Wu J, Wang Q, et al. Perioperative administration of erythropoietin combined with iron sucrose in gynecological tumor patients: a retrospective study. Int J Clin Exp Med 2017; 10:7111–7116.
Kaufner L, von Heymann C, Henkelmann A, et al. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing noncardiac surgery. Cochrane Database Syst Rev 2020; 8:CD012451.
Dousias V, Paraskevaidis E, Dalkalitsis N, et al. Recombinant human erythropoietin in mildly anemic women before total hysterectomy. Clin Exp Obstet Gynecol 2003; 30:235–238.
Larson B, Bremme K, Clyne N, et al. Preoperative treatment of anemic women with epoetin beta. Acta Obstet Gynecol Scand 2001; 80:559–562.
Tahir SS, Saeed K, Nazeer S, et al. Comparison of intravenous iron sucrose alone versus intravenous iron sucrose along with erythropoietin for management of anemia for gynecological patients waiting for surgery. Pak J Med Health Sci 2019; 13:566–569.
Kietpeerakool C, Supoken A, Laopaiboon M, et al. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database Syst Rev 2016; 2016:CD011732.
Lundin ES, Johansson T, Zachrisson H, et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand 2014; 93:335–344.
Abdul IF, Amadu MB, Adesina KT, et al. Adjunctive use of tranexamic acid to tourniquet in reducing haemorrhage during abdominal myomectomy - a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2019; 242:150–158.
Opoku-Anane J, Vargas MV, Marfori CQ, et al. Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 2020; 223:413.e1–413.e7.
Topsoee MF, Bergholt T, Ravn P, et al. Antihemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy: a double-blinded randomized placebo-controlled trial. Am J Obstet Gynecol 2016; 215:72.e1–72.e8.
Fusca L, Perelman I, Fergusson D, et al. The effectiveness of tranexamic acid at reducing blood loss and transfusion requirement for women undergoing myomectomy: a systematic review and meta-analysis. J Obstet Gynaecol Can 2019; 41:1185.e1–1192.e1.
Zakhari A, Sanders AP, Solnik MJ. Tranexamic acid in gynecologic surgery. Curr Med Res Opin 2020; 36:513–520.
Arthi PN, Jalakandan B, Gunaseelan S. Effect of prophylactic tranexamic acid on blood conservation in Indian women undergoing abdominal hysterectomy. Int J Reprod Contracept Obstet Gynecol 2018; 7:3538–3545.
Shady NW, Sallam HF, Fahmy H. Reducing blood loss during open myomectomy with intravenous versus topical tranexamic acid: a double-blinded randomized placebo-controlled trial. Middle East Fertil Soc J 2018; 23:225–231.
Martin-Hirsch PP, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2013; 2013:Cd001421.
Wali S, Balfoussia D, Touqmatchi D, et al. Misoprostol for open myomectomy: a systematic review and meta-analysis of randomised control trials. BJOG 2021; 128:476–483.
Mohamed SES, Mansour DY, Shaker AN. The effect of misoprostol on intra-operative blood loss during myomectomy operation: randomized controlled trial. Evidence Based Women Health J 2019; 9:363–371.
Khan QQ, Liaqat N, Shafqat T, et al. Efficacy of preoperative misoprostol in reducing hemorrhage during abdominal myomectomy. J Ayub Med Coll Abbottabad 2020; 32:198–203.
Paidas MJ, Hossain N, Shamsi TS, et al. Haemostasis and thrombosis in obstetrics and gynaecology. Chichester, West Sussex, UK: Wiley-Blackwell; 2011.
Butwick AJ, McDonnell N. Antepartum and postpartum anemia: a narrative review. Int J Obstet Anesth 2021; 47:102985.
Nair M, Choudhury MK, Choudhury SS, et al. Association between maternal anaemia and pregnancy outcomes: a cohort study in Assam, India. BMJ Glob Health 2016; 1:e000026.
Omotayo M, Abioye A, Kuyebi M, et al. Prenatal anemia and postpartum haemorrhage risk: a systematic review and meta-analysis. J Obstet Gynaecol Res 2020; 47:2565–2576.
Petty K, Waters JH, Sakamoto SB, et al. Antenatal anemia increases the risk of receiving postpartum red blood cell transfusions although the overall risk of transfusion is low. Transfusion 2018; 58:360–365.
Bergmann RL, Richter R, Bergmann KE, et al. Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol 2010; 150:126–131.
Patterson JA, Nippita TA, Randall D, et al. Outcomes associated with transfusion in low-risk women with obstetric haemorrhage. Vox Sang 2018; 113:678–685.
Chauleur C, Cochery-Nouvellon E, Mercier E, et al. Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort. Thromb Haemost 2008; 100:773–779.
James AH, Paglia MJ, Gernsheimer T, et al. Blood component therapy in postpartum hemorrhage. Transfusion 2009; 49:2430–2433.
Ehrenthal DB, Chichester ML, Cole OS, et al. Maternal risk factors for peripartum transfusion. J Women's Health (Larchmt) 2012; 21:792–797.
WHO guidelines for the management of postpartum haemorrhage and retained placenta. 2009. Available at: http://apps.who.int/iris/bitstream/10665/44171/1/9789241598514_eng.pdf . [Accessed 12 May 2022]
Cooper GM, McClure JH. Anaesthesia chapter from Saving mothers’ lives; reviewing maternal deaths to make pregnancy safer. Br J Anaesth 2008; 100:17–22.
Ushida T, Kotani T, Imai K, et al. Shock index and postpartum hemorrhage in vaginal deliveries: a multicenter retrospective study. Shock 2020; 55:332–337.
Drew T, Carvalho JCA, Subramanian C, et al. The association of shock index and haemoglobin variation with postpartum haemorrhage after vaginal delivery: a prospective cohort pilot study. Int J Obstet Anesth 2021; 45:67–73.
Lee SY, Kim HY, Cho GJ, et al. Use of the shock index to predict maternal outcomes in women referred for postpartum hemorrhage. Int J Gynaecol Obstet 2018; 144:221–224.
Maneschi F, Perrone S, Di Lucia A, et al. Shock parameters and shock index during severe postpartum haemorrhage and implications for management: a clinical study. J Obstet Gynaecol 2019; 40:40–45.
Nathan HL, El Ayadi A, Hezelgrave NL, et al. Shock index: an effective predictor of outcome in postpartum haemorrhage? BJOG 2014; 122:268–275.
Basil K, Castillo-Reyther R, Domínguez-Salgado LA, et al. Early prognostic capacity of serum lactate for severe postpartum hemorrhage. Obstetric Anesthesia Digest 2021; 41:173–173.
Sohn CH, Kim YJ, Seo DW, et al. Blood lactate concentration and shock index associated with massive transfusion in emergency department patients with primary postpartum haemorrhage. Br J Anaesth 2018; 121:378–383.
Attali E, Many A, Kern G, et al. Predicting the need for blood transfusion requirement in postpartum hemorrhage. J Matern Fetal Neonatal Med 2021; 35:7911–7916.
Epstein D, Solomon N, Korytny A, et al. Association between ionised calcium and severity of postpartum haemorrhage: a retrospective cohort study. Br J Anaesth 2021; 126:1022–1028.
Colucci G, Helsing K, Biasiutti FD, et al. Standardized management protocol in severe postpartum hemorrhage: a single-center study. Clin Appl Thromb Hemost 2018; 24:884–893.
Kacmar RM, Mhyre JM, Scavone BM, et al. The use of postpartum hemorrhage protocols in United States Academic Obstetric Anesthesia Units. Anesth Analg 2014; 119:906–910.
Gutierrez MC, Goodnough LT, Druzin M, et al. Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study. Int J Obstet Anesth 2012; 21:230–235.
Era S, Matsunaga S, Matsumura H, et al. Usefulness of shock indicators for determining the need for blood transfusion after massive obstetric hemorrhage. J Obstet Gynaecol Res 2014; 41:39–43.
Steele HB, Goetzl L. The practical utility of routine postpartum hemoglobin assessment. Am J Obstet Gynecol 2014; 210:576.e1–576.e6.
Patterson JA, Roberts CL, Bowen JR, et al. Blood transfusion during pregnancy, birth, and the postnatal period. Obstet Gynecol 2014; 123:126–133.
So-Osman C, Cicilia J, Brand A, et al. Triggers and appropriateness of red blood cell transfusions in the postpartum patient--a retrospective audit. Vox Sang 2010; 98:65–69.
Bonnet M-P, Deneux-Tharaux C, Dupont C, et al. Transfusion practices in postpartum hemorrhage: a population-based study. Acta Obstet Gynecol Scand 2013; 92:404–413.
Hamm RF, Perelman S, Wang EY, et al. Single-unit vs multiple-unit transfusion in hemodynamically stable postpartum anemia: a pragmatic randomized controlled trial. Am J Obstet Gynecol 2021; 224:84.e81–84.e87.
Solanki D, Ellis C, Hawkins T. Patient blood management in obstetric patients – south central region. Transfus Med 2018; 28:68.
Shehata N, Chassé M, Colas JA, et al. Risks and trends of red blood cell transfusion in obstetric patients: a retrospective study of 45,213 deliveries using administrative data. Transfusion 2017; 57:2197–2205.
Zdanowicz JA, Schneider S, Mueller M, et al. Red blood cell transfusion in obstetrics and its implication for patient blood management: a retrospective analysis in Switzerland from 1998 to 2016. Arch Gynecol Obstet 2021; 303:121–128.
Flores CJ, Sethna F, Stephens B, et al. Improving patient blood management in obstetrics: snapshots of a practice improvement partnership. BMJ Qual Improv Rep 2017; 6:e000009.
Thurn L, Wikman A, Westgren M, et al. Incidence and risk factors of transfusion reactions in postpartum blood transfusions. Blood Adv 2019; 3:2298–2306.
Maeda Y, Ogawa K, Morisaki N, et al. Association between perinatal anemia and postpartum depression: a prospective cohort study of Japanese women. Int J Gynaecol Obstet 2019; 148:48–52.
Wassef A, Nguyen QD, St-Andre M. Anaemia and depletion of iron stores as risk factors for postpartum depression: a literature review. J Psychosom Obstet Gynaecol 2019; 40:19–28.
Prick BW, Duvekot JJ, van der Moer PE, et al. Cost-effectiveness of red blood cell transfusion vs. nonintervention in women with acute anaemia after postpartum haemorrhage. Vox Sang 2014; 107:381–388.
Prick BW, Jansen AJ, Steegers EA, et al. Transfusion policy after severe postpartum haemorrhage: a randomised noninferiority trial. BJOG 2014; 121:1005–1014.
Thurn L, Wikman A, Lindqvist PG. Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism. Thromb Res 2018; 165:54–60.
Jiao C, Zheng L. Blood transfusion-related immunomodulation in patients with major obstetric haemorrhage. Vox Sang 2019; 114:861–868.
Chessman J, Patterson J, Nippita T, et al. Haemoglobin concentration following postpartum haemorrhage and the association between blood transfusion and breastfeeding: a retrospective cohort study. BMC Res Notes 2018; 11:686–686.
Drayton BA, Patterson JA, Nippita TA, et al. Red blood cell transfusion after postpartum haemorrhage and breastmilk feeding at discharge: a population-based study. Aust N Z J Obstet Gynaecol 2016; 56:591–598.
Cho GJ, Lee KM, Kim HY, et al. Postpartum haemorrhage requiring transfusion and risk of cardiovascular disease later in life: a retrospective cohort study. BJOG 2020; 128:738–744.
Cho GJ, Oh MS, Oh M-J, et al. Peripartum blood transfusions are associated with increased risk of cancer: a national retrospective cohort study. Clin Epidemiol 2020; 12:659–666.
Chua S, Gupta S, Curnow J, et al. Intravenous iron vs blood for acute postpartum anaemia (IIBAPPA): a prospective randomised trial. BMC Pregnancy Childbirth 2017; 17:424–1424.
Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang 2016; 112:122–131.
Goucher H, Wong CA, Patel SK, et al. Cell salvage in obstetrics. Anesth Analg 2015; 121:465–468.
Khan KS, Moore P, Wilson M, et al. A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial. Health Technol Assess 2018; 22:1–88.
Khan KS, Moore PAS, Wilson MJ, et al. SALVO study group. Cell salvage and donor blood transfusion during cesarean section: a pragmatic, multicentre randomised controlled trial (SALVO). PLoS Med 2017; 14:e1002471.
Lim G, Kotsis E, Zorn JM, et al. Cell salvage for postpartum haemorrhage during vaginal delivery: a case series. Blood Transfus 2018; 16:498–501.
Morikawa M, Kuramoto A, Nakayama M, et al. Intraoperative red cell salvage during obstetric surgery in 50 Japanese women. Int J Gynecol Obstet 2015; 128:256–259.
Liu Y, Li X, Che X, et al. Intraoperative cell salvage for obstetrics: a prospective randomized controlled clinical trial. BMC Pregnancy Childbirth 2020; 20:452–452.
McLoughlin C, Roberts TE, Jackson LJ, et al. SALVO study group. Cost-effectiveness of cell salvage and donor blood transfusion during caesarean section: results from a randomised controlled trial. BMJ Open 2019; 9:e022352.
Milne ME, Yazer MH, Waters JH. Red blood cell salvage during obstetric hemorrhage. Obstet Gynecol 2015; 125:919–923.
O’Flaherty D, Enright S, Ainle FN, et al. Intraoperative cell salvage as part of a blood conservation strategy in an obstetric population with abnormal placentation at a large Irish tertiary referral centre: an observational study. Ir J Med Sci 2020; 189:1053–1060.
Prabhu M, Bateman BT. Postpartum anemia: missed opportunities for prevention and recognition. Transfusion 2017; 57:3–5.
Froessler B, Cocchiaro C, Saadat-Gilani K, et al. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neonatal Med 2013; 26:654–659.
Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med 2018; 32:2797–2804.
Damineni SC, Thunga S. IV ferric carboxymaltose vs oral iron in the treatment of postpartum iron deficiency anaemia. J Clin Diagn Res 2016; 10:QC08–QC10.
Daniilidis A, Panteleris N, Vlachaki E, et al. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review. J Obstet Gynaecol 2017; 38:443–447.
Markova V, Norgaard A, Jørgensen KJ, et al. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev 2015; 2015:CD010861.
Froessler B, Dekker G, McAuliffe G. To the rescue: the role of intravenous iron in the management of severe anaemia in the peri-partum setting. Blood Transfus 2015; 13:150–152.
Oh KJ, Hong JS, Youm J, et al. Can coagulopathy in postpartum hemorrhage predict maternal morbidity? J Obstet Gynaecol Res 2016; 42:1509–1518.
De Lloyd L, Collins PW, Kaye A, et al. Early fibrinogen as a predictor of red cell requirements during postpartum haemorrhage. Int J Obstet Anesth 2012; 21:S13.
Shibata Y, Shigemi D, Ito M, et al. Association between fibrinogen levels and severity of postpartum hemorrhage in singleton vaginal deliveries at a Japanese perinatal center. J Nippon Med Sch 2014; 81:94–96.
Rigouzzo A, Louvet N, Favier R, et al. Assessment of coagulation by thromboelastography during ongoing postpartum hemorrhage. Anesth Analg 2020; 130:416–425.
Collins PW, Lilley G, Bruynseels D, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 2014; 124:1727–1736.
Precious EM, Alikhan R, Lilley G, et al. A prospective study to evaluate early clauss fibrinogen and fibtem as predictors of progression of major obstetric haemorrhage. J Thromb Haemost 2013; 11:425.
Ramler PI, Gillissen A, Henriquez DDCA, et al. Clinical value of early viscoelastometric point-of-care testing during postpartum hemorrhage for the prediction of severity of bleeding: a multicenter prospective cohort study in the Netherlands. Acta Obstet Gynecol Scand 2021; 100:1656–1664.
Peyvandi F, Biguzzi E, Franchi F, et al. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. J Thromb Haemost 2012; 10:1451–1453.
Yamada T, Akaishi R, Oda Y, et al. Antenatal fibrinogen concentrations and postpartum haemorrhage. Int J Obstet Anesth 2014; 23:365–370.
Kaufner L, Henkelmann A, von Heymann C, et al. Can prepartum thromboelastometry-derived parameters and fibrinogen levels really predict postpartum hemorrhage? J Perinat Med 2017; 45:427–435.
Haslinger C, Korte W, Hothorn T, et al. The impact of prepartum factor XIII activity on postpartum blood loss. J Thromb Haemost 2020; 18:1310–1319.
Matsunaga S, Masuko H, Takai Y, et al. Fibrinogen may aid in the early differentiation between amniotic fluid embolism and postpartum haemorrhage: a retrospective chart review. Sci Rep 2021; 11:8379–8379.
Green L, Knight M, Seeney F, et al. The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. Br J Haematol 2015; 172:616–624.
Cui C, Ma S, Qiao R. Prenatal plasma fibrinogen level predicts postpartum hemorrhage of patients with HELLP syndrome. Clin Appl Thromb Hemost 2020; 26:1076029619894057.
Karlsson O, Henriksson BA, Jeppsson A, et al. Coagulopathies early in postpartum haemorrhage; thromboelastography and haemostatic laboratory analyses. Thromb Res 2013; 131:S94.
Karlsson O, Jeppsson A, Hellgren M. Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both? Int J Obstet Anesth 2014; 23:10–17.
Roberts TCD, De Lloyd L, Bell SF, et al. Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. Int J Obstet Anesth 2021; 47:103192.
Toffaletti JG, Buckner KA. Use of earlier-reported rotational thromboelastometry parameters to evaluate clotting status, fibrinogen, and platelet activities in postpartum hemorrhage compared to surgery and intensive care patients. Anesth Analg 2019; 128:414–423.
Gillissen A, van den Akker T, Caram-Deelder C, et al. TeMpOH-1 study group. Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study. BMC Pregnancy Childbirth 2018; 18:398–398.
Henriquez DDCA, Bloemenkamp KWM, Loeff RM, et al. TeMpOH-1 study group. Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: a nationwide cohort study. Eur J Obstet Gynecol Reprod Biol 2019; 235:49–56.
Schol PBB, de Lange NM, Woiski MD, et al. Restrictive versus liberal fluid resuscitation strategy, influence on blood loss and hemostatic parameters in mild obstetric hemorrhage: an open-label randomized controlled trial. (REFILL study). PloS One 2021; 16:e0253765.
Bamberg C, Mickley L, Henkelmann A, et al. The impact of antenatal factor XIII levels on postpartum haemorrhage: a prospective observational study. Arch Gynecol Obstet 2018; 299:421–430.
Iwasa M, Shigemi D, Kido M, et al. The relationship between gestational thrombocytopenia and postpartum hemorrhage. J Obstet Gynaecol Res 2019; 45:1700.
van Dijk WEM, Nijdam JS, Haitjema S, et al. Platelet count and indices as postpartum hemorrhage risk factors: a retrospective cohort study. J Thromb Haemost 2021; 19:2873–2883.
Rottenstreich M, Rotem R, Glick I, et al. Mild gestational thrombocytopenia in primiparous women, does it affect risk of early postpartum hemorrhage? A retrospective cohort study. J Matern Fetal Neonatal Med 2021; 35:8426–8433.
Salomon C, de Moreuil C, Hannigsberg J, et al. Haematological parameters associated with postpartum haemorrhage after vaginal delivery: results from a French cohort study. J Gynecol Obstet Hum Reprod 2021; 50:102168.
de Lloyd L, Bovington R, Kaye A, et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth 2011; 20:135–141.
Işikalan MM, Özkaya EB, Özkaya B, et al. Does mild thrombocytopenia increase peripartum hemorrhage in elective cesarean deliveries? A retrospective cohort study. Int J Gynaecol Obstet 2021; 153:89–94.
Carlson LM, Dotters-Katz SK, Smid MC, et al. How low is too low? Postpartum hemorrhage risk among women with thrombocytopenia. Am J Perinatol 2017; 34:1135–1141.
Ge Z, Xia Z, Yuefang W, et al. Necessity of preoperative activated partial thromboplastin time test as a predictor for surgical hemorrhage in obstetric and gynecological patients in China. Clin Chim Acta 2017; 473:21–25.
Ducloy-Bouthors AS, Pilla C, Bauters A, et al. Point-of-care prothrombin time testing as an early predictor of severe post partum hemorrhage. Int J Gynaecol Obstet 2012; 119:S822–823.
Erhabor O, Isaac I, Muhammad A, et al. Some hemostatic parameters in women with obstetric hemorrhage in Sokoto, Nigeria. Int J Womens Health 2013; 5:285–291.
Karlsson O, Jeppsson A, Hellgren M. A longitudinal study of Factor XIII activity, fibrinogen concentration, platelet count and clot strength during normal pregnancy. Thromb Res 2014; 134:750–752.
Sharief LT, Lawrie AS, Mackie IJ, et al. Changes in factor XIII level during pregnancy. Haemophilia 2013; 20:e144–e148.
Karlsson O, Jeppsson A, Hellgren M. Factor XIII activity at onset of labour and association with postpartum haemorrhage: an exploratory posthoc study. Int J Obstet Anesth 2021; 47:103174.
Chevannes C, Harrod I, Bhalla A, et al. Fast rotational thromboelastometry evaluation in major obstetric haemorrhage. Br J Anaesth 2012; 109:484.
Lilley GJ, Burkett-St.Lawrent DA, Collins PW, et al. A prospective study to evaluate early clauss fibrinogen and fibtem as predictors for major obstetric haemorrhage. Int J Gynaecol Obstet 2013; 22:S7.
de Lange NM, Lance MD, de Groot R, et al. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv 2012; 67:426–435.
Lee J, Eley VA, Wyssusek K, et al. Rotational thromboelastometry (ROTEM) in obstetrics: baseline parameters in uncomplicated and complicated pregnancies. A prospective observational study on parturients. Anaesth Intensive Care 2018; 46:537.
Malina M, Jose S, Riddell A, et al. Thromboelastography in pregnancy: establishing reference ranges in third trimester and exploring predictive value for postpartum haemorrhage. J Thromb Haemost 2016; 14:161.
de Lange NM, van Rheenen-Flach LE, Lance MD, et al. Peri-partum reference ranges for ROTEM(R) thromboelastometry. Br J Anaesth 2014; 112:852–859.
Hill JS, Devenie G, Powell M. Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: developing a thrombelastography(R)-guided transfusion algorithm. Anaesth Intensive Care 2012; 40:1007–1015.
Butwick A, Ting V, Atkinson Ralls L, et al. The association between thromboelastographic parameters and total estimated blood loss in patients undergoing elective cesarean delivery. Anesth Analg 2011; 112:1041–1047.
Macafee B, Campbell JP, Ashpole K, et al. Reference ranges for thromboelastography (TEG ®) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia∗. Anaesthesia 2012; 67:741–747.
Ekelund K, Pinborg A, Bjerrum OW, et al. Thromboelastography and aggregometry guided treatment in a patient with idiopathic thrombocytopenic purpura and postpartum hemorrhage. Acta Anaesthesiol Scand 2013; 57:16–17.
Roberts I, Shakur H, Fawole B, et al. Haematological and fibrinolytic status of Nigerian women with postpartum haemorrhage. BMC Pregnancy Childbirth 2018; 18:143–143.
McNamara H, Kenyon C, Smith R<ET-A>. Four years’ experience of a ROTEM®-guided algorithm for treatment of coagulopathy in obstetric haemorrhage. Anaesthesia 2019; 74:984–991.
Collins PW, Cannings-John R, Bruynseels D, et al. OBS2 study collaborators. Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. Br J Anaesth 2017; 119:422–434.
Bell SF, Collis RE, Bailey C, et al. The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. Int J Obstet Anesth 2021; 47:102983.
Ballard K, Kalanithy P, Al-Obaidi M, et al. Reduced wastage of fresh frozen plasma after introduction of ROTEM in clinical areas during major obstetric haemorrhage. Transfus Med 2019; 29:52.
Cohen L, Collis R, Collins PW, et al. ROTEMsigma and TEG6 trauma algorithms do not guide platelet transfusion in postpartum haemorrhage. Int J Obstet Anesth 2019; 39:9.
Susen S, Tournoys A, Duhamel A, et al. Tranexamic acid inhibits fibrinolysis-induced coagulopathy associated with postpartum hemorrhage. J Thromb Haemost 2013; 11:221.
Arnolds DE, Scavone BM. Thromboelastographic assessment of fibrinolytic activity in postpartum hemorrhage: a retrospective single-center observational study. Anesth Analg 2020; 131:1373–1379.
Waters JH, Bonnet MP. When and how should I transfuse during obstetric hemorrhage? Int J Obstet Anesth 2021; 46:102973.
Sullivan EA, Henry A, McQuilten ZK, et al. Massive obstetric haemorrhage requiring rapid transfusion in Australia and New Zealand. J Paediatr Child Health 2018; 54:113–114.
Maher N, Gleeson N, Darcy T, et al. Comparison of blood transfusion and surgical complications in peripartum hysterectomy when anticipated and unanticipated. J Obstet Gynaecol 2015; 36:15–18.
Aoki NJ, Venardos K, Andrianopoulos N, et al. Use of blood components in major obstetric hemorrhage: preliminary findings from the Australian and New Zealand massive transfusion registry (ANZ-MTR). Blood 2014; 124:1563.
Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. Obstet Anesth Dig 2018; 38:82–83.
Pasquier P, Gayat E, Rackelboom T, et al. An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. Anesth Analg 2013; 116:155–161.
Henriquez DD, Caram-Deelder C, Le Cessie S, et al. Timing of plasma transfusion and adverse maternal outcome in women with persistent postpartum hemorrhage: a nationwide cohort study. Vox Sang 2019; 114:221.
Henriquez DDCA, Caram-Deelder C, le Cessie S, et al. TeMpOH-1 Research Group. Association of timing of plasma transfusion with adverse maternal outcomes in women with persistent postpartum hemorrhage. JAMA Netw Open 2019; 2:e1915628.
Jones RM, de Lloyd L, Kealaher EJ, et al. collaborators. Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia 2016; 71:648–656.
Jones R, Hamlyn V, Collis RE, et al. Platelets in postpartum haemorrhage: who needs them? Int J Obstet Anesth 2015; 24:S10.
Teofili L, Bianchi M, Zanfini BA, et al. Acute lung injury complicating blood transfusion in postpartum hemorrhage: incidence and risk factors. Mediterr J Hematol Infect Dis 2014; 6:e2014069.
Teofili L, Bianchi M, Zanfini BA, et al. Pregnancy-related hypertensive disorders are the major risk factor for TRALI in patients with severe postpartum hemorrhage. Blood 2013; 122:1159.
Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth 2017; 119:411–421.
Ducloy-Bouthors AS, Mercier FJ, Grouin JM, et al. FIDEL working group. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG 2021; 128:1814–1823.
Ducloy-Bouthors A-S, Mignon A, Huissoud C, et al. Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: a study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial. Anaesth Crit Care Pain Med 2016; 35:293–298.
Zaidi A, Kohli R, Daru J, et al. Early use of fibrinogen replacement therapy in postpartum hemorrhage—a systematic review. Transfus Med Rev 2020; 34:101–107.
Wikkelso AJ, Edwards HM, Afshari A, et al. Preemptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth 2015; 114:623–633.
Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia 2015; 70: (Suppl 1): 78–86. e27-78.
Cunningham FG, Nelson DB. Disseminated intravascular coagulation syndromes in obstetrics. Obstet Gynecol 2015; 126:999–1011.
Ahmed S, Byrne BM. How efficient is fibrinogen concentrate in the management of major obstetric haemorrhage in comparison to cryoprecipitate? Int J Gynaecol Obstet 2012; 119:S818.
Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. Transfus Med 2012; 22:344–349.
Kamidani R, Miyake T, Okada H, et al. Effect of cryoprecipitate transfusion therapy in patients with postpartum hemorrhage: a retrospective cohort study. Sci Rep 2021; 11:18458–18458.
Green L, Daru J, Dodds J, et al. Effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage (ACROBAT) in the UK: a protocol for a pilot cluster randomised trial. BMJ Open 2020; 10:e036416.
Matsunaga S, Takai Y, Nakamura E, et al. The clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia. Sci Rep 2017; 7:46749.
Sahin AS, Ozkan S. Treatment of obstetric hemorrhage with fibrinogen concentrate. Med Sci Monit 2019; 25:1814–1821.
Mallaiah S, Barclay P, Harrod I, et al. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 2014; 70:166–175.
Wikkelsoe AJ, Afshari A, Stensballe J, et al. The FIB-PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials 2012; 13:110.
Makino S, Takeda S, Kobayashi T, et al. National survey of fibrinogen concentrate usage for postpartum hemorrhage in Japan: investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 2015; 41:1155–1160.
Seto S, Itakura A, Okagaki R, et al. An algorithm for the management of coagulopathy from postpartum hemorrhage, using fibrinogen concentrate as first-line therapy. Int J Obstet Anesth 2017; 32:11–16.
Karlsson O, Sporrong T, Hillarp A, et al. Prospective longitudinal study of thromboelastography and standard hemostatic laboratory tests in healthy women during normal pregnancy. Anesth Analg 2012; 115:890–898.
Hall DR. Abruptio placentae and disseminated intravascular coagulopathy. Semin Perinatol 2009; 33:189–195.
Shakur H, Beaumont D, Pavord S, et al. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev 2018; 2:CD012964.
WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389:2105–2116.
Vogel JP, Oladapo OT, Dowswell T, et al. Updated WHO recommendation on intravenous tranexamic acid for the treatment of postpartum haemorrhage. Lancet Glob Health 2018; 6:e18–e19.
Saccone G, Della Corte L, D’Alessandro P, et al. Prophylactic use of tranexamic acid after vaginal delivery reduces the risk of primary postpartum hemorrhage. J Matern Fetal Neonatal Med 2019; 33:3368–3376.
Sentilhes L, Winer N, Azria E, et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med 2018; 379:731–742.
Bellos I. Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis. Am J Obstet Gynecol 2021; 226:510.e2–523.e22.
Sentilhes L, Sénat M V, Le Lous M, et al. Tranexamic acid for the prevention of blood loss after cesarean delivery. Obstetric Anesthesia Digest 2021; 41:159–159.
Ker K, Roberts I, Chaudhri R, et al. WOMAN-2 trial collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials 2018; 19:712.
Shander A, Javidroozi M, Sentilhes L. Tranexamic acid and obstetric hemorrhage: give empirically or selectively? Int J Obstet Anesth 2021; 48:103206.
Arribas M, Roberts I, Chaudhri R, et al. WOMAN-PharmacoTXA trial: study protocol for a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous and oral administration of tranexamic acid in women giving birth by caesarean section. Wellcome Open Res 2021; 6:157.
Xia Y, Griffiths BB, Xue Q. Tranexamic acid for postpartum hemorrhage prevention in vaginal delivery: a meta-analysis. Medicine (Baltimore) 2020; 99:e18792.
Frimat M, Decambron M, Lebas C, et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis 2016; 68:50–57.
Walsh M, Ploplis V, Fritz B, et al. Successful thromboelastographic goal-directed blood component therapy, prothrombin complex concentrate, and rFVIIa administration without tranexamic acid for reversal of severe coagulopathy in an obstetrical patient presenting with hemorrhagic cardiac arrest. Am J Hematol 2014; 89:E50.
Tarabrin O, Mazurenko A, Potapchuk Y, et al. Reducing the level of blood loss in patients with obstetric massive bleeding. Crit Care 2017; 21:28–29.
Ronenson AM, Shifman EM, Kulikov AV, et al. New opportunities for using a prothrombin complex concentrate in postpartum haemorrhage: a multicentre retrospective study. Voprosy ginekologii, akušerstva i perinatologii 2020; 19:72–77.
Bienstock JL, Eke AC, Hueppchen NA. Postpartum hemorrhage. N Engl J Med 2021; 384:1635–1645.
Kayem G, Kurinczuk JJ, Alfirevic Z, et al. Specific second-line therapies for postpartum haemorrhage: a national cohort study. BJOG 2011; 118:856–864.
Wang CY, Chen YC, Lin CH, et al. Successful treatment with recombinant blood factor VIIa in severe postpartum hemorrhage-induced disseminated intravascular coagulation. Taiwan J Obstet Gynecol 2016; 55:301–302.
Kiranaggarwalteenu S, Bansal T. Recombinant activated factor VII: a savior in management of postpartum hemorrhage. Anaesth Pain Intensive Care 2016; 20:227–229.
Magon N, Babu KM, Kapur K, et al. Recombinant activated factor VII in post partum haemorrhage. Niger Med J 2013; 54:289–294.
Ogawa M, Akahira S, Takahashi S, et al. Low-dose recombinant activated factor VII temporally stopped bleeding from small artery in severe postpartum hemorrhage: a case report. Blood Coagul Fibrinolysis 2013; 24:344–346.
Quigley JB, Byrne J, Diaz M, et al. Use of recombinant factor VIIa (rFVIIa) in acute life threatening primary postpartum haemorrhage: a case report. Vox Sang 2013; 105:272–273.
Park SC, Yeom SR, Han SK, et al. Recombinant activated factor VII as a second line treatment for postpartum hemorrhage. Korean J Crit Care Med 2017; 32:333–339.
Barillari G, Frigo MG, Casarotto M, et al. Use of recombinant activated factor VII in severe postpartum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study. Thromb Res 2009; 124:41–47.
Mostic T, Sparic R, Argirovic R, et al. Our experience with the use of recombinant activated factor VII in postpartum haemorrhage. Srp Arh Celok Lek 2008; 136: (Suppl 3): 204–209.
Seidlova D, Blatny J, Penka M, et al. Recombinant activated factor VII in the treatment of life threatening postpartum haemorrhage; registry UniSeven in the Czech Republic. Ceska Gynekol 2010; 75:297–305.
Kim SC, Kang SY, Lee YJ, et al. Clinical efficacy of recombinant activated factor VII in postpartum hemorrhage. J Perinat Med 2013; 41:135.
Corona-Gutierrez AA, Garcia-Ruan K, Camarena-Pulido EE, et al. Use of recombinant activated factor VII in severe obstetric hemorrhage [Spanish]. Ginecol Obstet Mex 2018; 86:779–786.
Murakami M, Kobayashi T, Kubo T, et al. Experience with recombinant activated factor VII for severe postpartum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 2015; 41:1161–1168.
Lavigne-Lissalde G, Aya G, Mercier F, et al. rhuFVIIa in women with a refractory primary postpartum haemorrhage: an international, multicenter, randomised, opened, controlled trial. Thromb Res 2013; 131:S74.
Alkhalid Y, Lagman C, Sheppard JP, et al. Restrictive transfusion threshold is safe in high-risk patients undergoing brain tumor surgery. Clin Neurol Neurosurg 2017; 163:103–107.
Dasenbrock HH, Devine CA, Liu KX, et al. Thrombocytopenia and craniotomy for tumor: a National Surgical Quality Improvement Program analysis. Cancer 2016; 122:1708–1717.
He G, Luo W, Qin H, et al. Ultrasound-guided intratumoral radiofrequency ablation coagulation to facilitate meningioma resection: preliminary experience. J Ultrasound Med 2018; 37:577–583.
Karsy M, Yoon N, Boettcher L, et al. Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neurooncol 2018; 138:123–132.
Khoury MN, Missios S, Edwin N, et al. Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. Neurooncol Pract 2016; 3:87–96.
Manaka H, Sakata K, Tatezuki J, et al. Safety and efficacy of preoperative embolization in patients with meningioma. J Neurol Surg 2018; 79: (Suppl 4): S328–S333.
Neef V, Koenig S, Monden D, et al. Clinical outcome and risk factors of red blood cell transfusion in patients undergoing elective primary meningioma resection. Cancers 2021; 13:3601.
Nguyen HS, Janich K, Doan N, et al. Extent of T1+C intensity is a predictor of blood loss in resection of meningioma. World Neurosurg 2017; 101:69–75.
Sheppard J, Romiyo P, Nguyen T, et al. Risk factors for platelet transfusion in glioblastoma surgery. Neuro Oncol 2017; 19: (Suppl 6): vi108.
Sugiu K, Hishikawa T, Hiramatsu M, et al. Important role and future perspective of embolization for intra-cranial tumors. Jpn J Neurosurg 2020; 29:543–552.
Cohen JA, Alan N, Seicean A, et al. Risk associated with perioperative red blood cell transfusion in cranial surgery. Neurosurg Rev 2017; 40:633–642.
Adelmann D, Klaus DA, Krenn CG, et al. Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy. Br J Anaesth 2014; 113:628–633.
Skardelly M, Monch L, Roder C, et al. Survey of the management of perioperative bridging of anticoagulation and antiplatelet therapy in neurosurgery. Acta Neurochir (Wien) 2018; 160:2077–2085.
Prior A, Fiaschi P, Zona G, et al. Clinical practice for antiplatelet and anticoagulant therapy in neurosurgery: data from an Italian survey and summary of current–recommendations - part I, antiplatelet therapy. Neurosurg Rev 2021; 44:485–493.
Hanalioglu S, Sahin B, Sahin OS, et al. Effect of perioperative aspirin use on hemorrhagic complications in elective craniotomy for brain tumors: results of a single-center, retrospective cohort study. J Neurosurg 2020; 132:1529–1538.
Ebel F, Ullmann M, Guzman R, et al. Does the discontinuation time of antiplatelet or anticoagulation treatment affect hemorrhagic complications in patients undergoing craniotomy for neurovascular lesions? Brit J Neurosurg 2021; 35:619–624.
Anker-Moller T, Troldborg A, Sunde N, et al. Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review. Semin Thromb Hemost 2017; 43:750–758.
Prastikarunia R, Wahyuhadi J, Susilo RI, et al. Tranexamic acid to reduce operative blood loss in brain tumor surgery: a meta-analysis. Surg Neurol Int 2021; 12:345.
Ravi GK, Panda N, Ahluwalia J, et al. Effect of tranexamic acid on blood loss, coagulation profile, and quality of surgical field in intracranial meningioma resection: a prospective randomized, double-blind, placebo-controlled study. Surg Neurol Int 2021; 12:272.
Agarwal P, Abdullah KG, Ramayya AG, et al. A retrospective propensity score-matched early thromboembolic event analysis of prothrombin complex concentrate vs fresh frozen plasma for warfarin reversal prior to emergency neurosurgical procedures. Neurosurgery 2018; 82:877–886.
Gulati D, Dua D, Torbey MT. Hemostasis in intracranial hemorrhage. Front Neurol 2017; 8:80.
Arnone GD, Kumar P, Wonais MC, et al. Impact of platelet transfusion on intracerebral hemorrhage in patients on antiplatelet therapy-an analysis based on intracerebral hemorrhage score. World Neurosurg 2018; 111:e895–e904.
Feldman EA, Meola G, Miller CD, et al. Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage∗. Crit Care Med 2020; 47:1759–1765.
Hollingworth M, Krishnan K, Dineen R, et al. Does tranexamic acid improve outcome for patients with surgically treated intra-cerebral haemorrhage: results from the tranexamic acid for intra-cerebral haemorrhage-2 (TICH-2) trial. Int J Stroke 2020; 15:112–112.
Huang B, Xu Q, Ye R, et al. Influence of tranexamic acid on cerebral hemorrhage: a meta-analysis of randomized controlled trials. Clin Neurol Neurosurg 2018; 171:174–178.
Dhar R, Zazulia AR, Derdeyn CP, et al. RBC transfusion improves cerebral oxygen delivery in subarachnoid hemorrhage. Crit Care Med 2017; 45:653–659.
Luostarinen T, Lehto H, Skrifvars MB, et al. Transfusion frequency of red blood cells, fresh frozen plasma, and platelets during ruptured cerebral aneurysm surgery. World Neurosurg 2015; 84:446–450.
Darveau SC, Pertsch NJ, Toms SA, et al. Short term outcomes associated with patients requiring blood transfusion following elective laminectomy and fusion for lumbar stenosis: a propensity-matched analysis. J Clin Neurosci 2021; 90:184–190.
De la Garza Ramos R, Gelfand Y, Benton JA, et al. Rates, risk factors, and complications of red blood cell transfusion in metastatic spinal tumor surgery: an analysis of a prospective multicenter surgical database. World Neurosurg 2020; 139:e308–e315.
Almeida ND, Lee R, Wei C, et al. Coagulation profile as a significant risk factor for short-term complications and mortality after anterior cervical discectomy and fusion. World Neurosurg 2021; 148:e74–e86.
Rajan S, Babu K, Tosh P. Effect of intraoperative vasopressor use on free flap outcome following major head-and-neck reconstructive surgeries. J Head Neck Phys Surg 2020; 8:76–79.
Douglas D, Das P, Moss C, et al. Implementation of a preoperative anemia care pathway in elective spinal surgery patients. J Neurosurg Anesthesiol 2020; 32:e9.
Alfonso AR, Hutzler L, Lajam C, et al. Institution-wide blood management protocol reduces transfusion rates following spine surgery. Int J Spine Surg 2019; 13:270–274.
Chen J, Li K, Chen Q, et al. Meta-analysis of the efficacy and safety of tranexamic acid in open spinal surgery. Chin J Tissue Eng Res 2020; 25:1458–1464.
Zadeh FJ, Janatmakan F, Tonekaboni MS, et al. The effect of fibrinogen on blood loss after lumbar surgery: a double-blind randomized clinical trial. Anesth Pain Med 2019; 9:e91199.
Faraoni D, Meier J, New HV, et al. Patient blood management for neonates and children undergoing cardiac surgery: 2019 NATA guidelines. J Cardiothorac Vasc Anesth 2019; 33:3249–3263.
Roullet S, de Maistre E, Ickx B, et al. Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: what role for which indication in bleeding situations? Anaesth Crit Care Pain Med 2019; 38:539–548.
Goobie SM, Gallagher T, Gross I, et al. Society for the advancement of blood management administrative and clinical standards for patient blood management programs. 4th edition (pediatric version). Paediatr Anaesth 2019; 29:231–236.
Valentine SL, Bembea MM, Muszynski JA, et al. Pediatric Critical Care Transfusion and Anemia Expertise Initiative (TAXI), Pediatric Critical Care Blood Research Network (BloodNet), and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Consensus recommendations for RBC transfusion practice in critically ill children from the pediatric critical care transfusion and anemia expertise initiative. Pediatr Crit Care Med 2018; 19:884–898.
Siemens K, Sangaran DP, Hunt BJ, et al. Antifibrinolytic drugs for the prevention of bleeding in pediatric cardiac surgery on cardiopulmonary bypass: a systematic review and meta-analysis. Anesth Analg 2021; 134:987–1001.
Fenger-Eriksen C, D’Amore Lindholm A, Norholt SE, et al. Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial. Br J Anaesth 2019; 122:760–766.
Fischer MO, Guinot PG, Debroczi S, et al. Individualised or liberal red blood cell transfusion after cardiac surgery: a randomised controlled trial. Br J Anaesth 2022; 128:37–44.
Fogagnolo A, Taccone FS, Vincent JL, et al. Using arterial-venous oxygen difference to guide red blood cell transfusion strategy. Crit Care 2020; 24:160.
Prado L, Lobo F, de Oliveira N, et al. Intraoperative haemodynamic optimisation therapy with venoarterial carbon dioxide difference and pulse pressure variation - does it work? Anaesthesiol Intensive Ther 2020; 52:297–303.
László I, Janovszky Á, Lovas A, et al. Effects of goal-directed crystalloid vs. colloid fluid therapy on microcirculation during free flap surgery: a randomised clinical trial. Eur J Anaesthesiol 2019; 36:592–604.
Kabon B, Sessler DI, Kurz A. Crystalloid–Colloid Study Team. Effect of intraoperative goal-directed balanced crystalloid versus colloid administration on major postoperative morbidity: a randomized trial. Anesthesiology 2019; 130:728–744.
Yang JC, Xu CX, Sun Y, et al. Balanced ratio of plasma to packed red blood cells improves outcomes in massive transfusion: a large multicenter study. Exp Ther Med 2015; 10:37–42.
Delaney M, Stark PC, Suh M, et al. Massive transfusion in cardiac surgery: the impact of blood component ratios on clinical outcomes and survival. Anesth Analg 2017; 124:1777–1782.
Mazzeffi MA, Chriss E, Davis K, et al. Optimal plasma transfusion in patients undergoing cardiac operations with massive transfusion. Ann Thorac Surg 2017; 104:153–160.
Tsukinaga A, Maeda T, Takaki S, et al. Relationship between fresh frozen plasma to packed red blood cell transfusion ratio and mortality in cardiovascular surgery. J Anesth 2018; 32:539–546.
Hogen R, Dhanireddy K, Clark D, et al. Balanced blood product transfusion during liver transplantation. Clin Transplant 2018; 32:e1391.
Sadacharam K, Brenn BR, Zhang Y, et al. Fresh frozen plasma-to-red blood cell ratio is an independent predictor of blood loss in patients with neuromuscular scoliosis undergoing posterior spinal fusion. Spine J 2020; 20:369–379.
Davis BH, Jungerius B. International Council for Standardization in Haematology (ICSH). International Council for Standardization in Haematology technical report 1-2009: new reference material for haemiglobincyanide for use in standardization of blood haemoglobin measurements. Int J Lab Hematol 2010; 32:139–141.
Karakochuk CD, Hess SY, Moorthy D, et al. HEmoglobin MEasurement (HEME) Working Group. Measurement and interpretation of hemoglobin concentration in clinical and field settings: a narrative review. Ann N Y Acad Sci 2019; 1450:126–146.
Shander A, Corwin HL. A narrative review on hospital-acquired anemia: keeping blood where it belongs. Transfus Med Rev 2020; 34:195–199.
Shander A, Gilsanz F. Monitoring, safety and efficiency in the use of blood components. Rev Esp Anestesiol Reanim 2017; 64:1–5.
Barker SJ, Shander A, Ramsay MA. Continuous noninvasive hemoglobin monitoring: a measured response to a critical review. Anesth Analg 2016; 122:565–572.
Suehiro K, Joosten A, Alexander B, et al. Continuous noninvasive hemoglobin monitoring. Curr Opin Crit Care 2015; 21:265–270.
Xu T, Yang T, Kim JB, et al. Evaluation of noninvasive hemoglobin monitoring in surgical critical care patients∗. Crit Care Med 2016; 44:e344–e352.
García-Soler P, Camacho Alonso JM, González-Gómez JM, et al. Noninvasive hemoglobin monitoring in critically ill pediatric patients at risk of bleeding. Med Intensiva 2017; 41:209–215.
Zortéa T, Wizbicki DPdS, Madeira K, et al. Noninvasive hemoglobin monitoring in clinical trials: a systematic review and meta-analysis. Braz J Anesthesiol (English Edition) 2020; 70:388–397.
Shabaninejad H, Ghadimi N, Sayehmiri K, et al. Comparison of invasive and noninvasive blood hemoglobin measurement in the operating room: a systematic review and meta-analysis. J Anesth 2019; 33:441–453.
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1). Available at: http://www.who.int/vmnis/indicators/haemoglobin.pdf . [Accessed 4 July 2022]
Shander A, Knight K, Thurer R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116: (Suppl 7A): 58S–69S.
Lasocki S, Krauspe R, von Heymann C, et al. PREPARE: the prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery: a multicentre, observational study. Eur J Anaesthesiol 2015; 32:160–167.
Munoz M, Acheson AG, Bisbe E, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia 2018; 73:1418–1431.
Kim YW, Bae JM, Park YK, et al. FAIRY Study Group. Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: the FAIRY Randomized Clinical Trial. JAMA 2017; 317:2097–2104.
Xu H, Duan Y, Yuan X, et al. Intravenous iron versus placebo in the management of postoperative functional iron deficiency anemia in patients undergoing cardiac valvular surgery: a prospective, single-blinded, randomized controlled trial. J Cardiothorac Vasc Anesth 2019; 33:2941–2948.
Laso-Morales MJ, Vives R, Gomez-Ramirez S, et al. Intravenous iron administration for postoperative anaemia management after colorectal cancer surgery in clinical practice: a single-centre, retrospective study. Blood Transfus 2018; 16:338–342.
Madi-Jebara SN, Sleilaty GS, Achouh PE, et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18:59–63.
Karkouti K, McCluskey SA, Ghannam M, et al. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Can J Anaesth 2006; 53:11–19.
Garrido-Martin P, Nassar-Mansur MI, de la Llana-Ducros R, et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact Cardiovasc Thorac Surg 2012; 15:1013–1018.
Bisbe E, Molto L, Arroyo R, et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth 2014; 113:402–409.
Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br 2005; 87:213–217.
Sutton PM, Cresswell T, Livesey JP, et al. Treatment of anaemia after joint replacement. A double-blind, randomised, controlled trial of ferrous sulphate versus placebo. J Bone Joint Surg Br 2004; 86:31–33.
Weatherall M, Maling TJ. Oral iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ J Surg 2004; 74:1049–1051.
Zauber NP, Zauber AG, Gordon FJ, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267:525–527.
Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am 2010; 92:265–269.
Crosby L, Palarski VA, Cottington E, et al. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart Lung 1994; 23:493–499.
Gomez-Ramirez S, Maldonado-Ruiz MA, Campos-Garrigues A, et al. Short-term perioperative iron in major orthopedic surgery: state of the art. Vox Sang 2019; 114:3–16.
Mudge DW, Tan KS, Miles R, et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation 2012; 93:822–826.
Yoo S, Bae J, Ro DH, et al. Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: a randomised controlled trial. Eur J Anaesthesiol 2021; 38:358–365.
Lee B, Kim EJ, Song J, et al. A randomised trial evaluating the effect of intraoperative iron administration. Sci Rep 2020; 10:15853.
Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer(R)) reduces postoperative anaemia in preoperatively nonanaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109:257–266.
Weltert L, Rondinelli B, Bello R, et al. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. Transfusion 2015; 55:1644–1654.
Cuenca J, Garcia-Erce JA, Martinez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery. Transfusion 2006; 46:1112–1119.
Ali SME, Hafeez MH, Nisar O, et al. Role of preoperative erythropoietin in the optimization of preoperative anemia among surgical patients - a systematic review and meta-analysis. Hematol Transfus Cell Ther 2021; 44:76–84.
Biboulet P, Motais C, Pencole M, et al. Preoperative erythropoietin within a patient blood management program decreases both blood transfusion and postoperative anemia: a prospective observational study. Transfusion 2020; 60:1732–1740.
NICE guideline [NG24] Blood Transfusion 2015. Available at: https://www.nice.org.uk/guidance/ng24 . [Accessed 4 July 2022]
American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management∗. Anesthesiology 2015; 122:241–275.
Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 316:2025–2035.
Farmer SL, Towler SC, Leahy MF, et al. Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA). Best Pract Res Clin Anaesthesiol 2013; 27:43–58.
Koch CG, Li L, Sun Z, et al. Hospital-acquired anemia: prevalence, outcomes, and healthcare implications. J Hosp Med 2013; 8:506–512.
Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36:2667–2674.
Shander A, Goodnough LT. Why an alternative to blood transfusion? Crit Care Clin 2009; 25:261–277.
Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113:3406–3417.
European Board of Anaesthesiology (EBA UEMS). EPD–Standing Committee - Education and Professional Development. 2016. Available at: https://www.eba-uems.eu/Education/education.html . [Accessed 4 July 2022]
Kietaibl S. Facilitating the implementation of perioperative patient blood management: education, infrastructure, process descriptions, quality indicators and patient information. Austin J Anesth Analg 2019; 7:1079.